AAV capsid 3D molecular surface feature mapping

Characterizing AAV capsid surface features using DNA-encoded libraries addresses tissue selectivity issues, enabling targeted AAV delivery and improved therapeutic efficacy.

CN119095970APending Publication Date: 2024-12-06SHANGHAI XINSHENG TANTU TECHNOLOGY CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202380035968.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-25
Filing Date
2023-04-24
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing AAV therapies face limitations due to tissue or cell type selectivity, particularly for central nervous system-related diseases, necessitating the development of AAV capsid variants for targeted delivery.

Method used

Characterization of 3D molecular surface features of AAV capsids using DNA-encoded libraries (DECLs, DEALs, phage display libraries, DNA/RNA aptamer libraries) through aptamer or DNA-encoded chemical binding, identifying and quantifying binders to map surface features.

Benefits of technology

Enables the development of AAV capsid variants with improved tissue and cell type specificity, enhancing therapeutic delivery efficiency and reducing immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095970A_ABST
    Figure CN119095970A_ABST
Patent Text Reader

Abstract

The present disclosure provides compositions and methods for obtaining and mapping 3D molecular surface characteristics of viral capsids (e.g., AAV capsids).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority claim

[0002] This application claims the benefit of U.S. Provisional Application Nos. 63 / 334,590, filed on April 25, 2022; 63 / 334,595, filed on April 25, 2022; and 63 / 334,596, filed on April 25, 2022. The entire contents of the foregoing are incorporated into this disclosure by reference. Technical Field

[0003] The present disclosure relates to compositions and methods for obtaining and mapping 3D features of viral capsids (e.g., AAV capsids). Background Art

[0004] Gene therapy using adeno-associated virus (AAV) as a vector has emerged as a new therapeutic modality with the potential to achieve substantial disease modification and cure in many monogenic diseases.

[0005] AAV therapies have shown promise in a wide range of applications, such as restoring blood clotting function in hemophilia patients, restoring vision in patients with Leber congenital amaurosis (a rare inherited form of blindness), and halting the progression of spinal muscular atrophy in infants, bringing true breakthrough innovation to patients.

[0006] However, treatment of many diseases using AAV therapeutics is limited by the tissue or cell type selectivity of AAV capsid variants. Gene therapy therapeutics in particular exhibit very low tropism, especially for central nervous system-related diseases.

[0007] The treatment of rare diseases, cancer, and other organ-, tissue-, or cell-type-restricted disease states would be greatly facilitated by the development of AAV capsid variants for targeted delivery of therapeutics to desired organs, tissues, or cell types.

[0008] Therefore, there is a need in the art for methods to map the 3D molecular features of AAV capsids for use in developing AAV capsid variants. Summary of the invention

[0009] The present disclosure relates to methods for obtaining and analyzing 3D molecular surface features of AAV (adeno-associated virus) capsid variants using the binding properties of DNA-encoded libraries (DELs), such as DNA-encoded chemical libraries (DECLs) and DNA-encoded antibody libraries (DEALs), phage display libraries, DNA aptamer libraries (single-stranded and circular aptamers), RNA aptamer libraries (single-stranded and circular aptamers), or combinations thereof.

[0010] Thus, the present disclosure provides a method for characterizing the 3D molecular surface features of an AAV capsid, comprising:

[0011] a) contacting the AAV capsid with a library of aptamers targeting one or more AAV capsids;

[0012] b) removing unbound aptamers;

[0013] c) eluting the bound aptamer;

[0014] d) identifying aptamers that bind to AAV capsids;

[0015] e) determining the presence and / or level of the identified aptamer; and

[0016] f) Characterizing the 3D molecular surface features of the AAV capsid based on the presence and / or levels of the identified aptamers.

[0017] In some embodiments, steps a)-c) are repeated 1, 2, 3 or more times.

[0018] In some embodiments, the eluted aptamers are amplified by a PCR reaction.

[0019] In some embodiments, the aptamers in the aptamer library are linear aptamers or circular aptamers.

[0020] In some embodiments, each aptamer in the aptamer library includes at least one primer binding region and a random sequence.

[0021] In some embodiments, the primer binding region of the aptamers in the aptamer library is about 20 bp in length.

[0022] In some embodiments, the random sequences of aptamers in the aptamer library are about 36 to about 40 bp in length.

[0023] In some embodiments, each aptamer in the aptamer library comprises a double-stranded oligonucleotide sequence.

[0024] In some embodiments, each aptamer in the aptamer library comprises a single-stranded oligonucleotide sequence.

[0025] In some embodiments, at least one aptamer of the aptamer library is capable of binding to a target on the AAV capsid through a random sequence.

[0026] In some embodiments, each aptamer in the aptamer library includes a single-stranded DNA (Guard-DNA or G-DNA) that is complementary to a region of the DNA aptamer including the 5'-extension region.

[0027] In some embodiments, when the AAV capsid is contacted with the aptamer library, the single-stranded G-DNA molecule is released.

[0028] In some embodiments, identification of an adaptor that binds to an AAV capsid comprises: contacting the mixture obtained in step a) with RNase H and a single-stranded RNA complementary to G-DNA, wherein a fluorophore and a quencher are labeled at the 5' end and the 3' end of the single-stranded RNA, respectively; and measuring the fluorescence intensity of the mixture.

[0029] In some embodiments, the fluorophore is selected from the group consisting of fluorescein, tetramethylrhodamine, Cy5, Cy3, and Texas Red.

[0030] In some embodiments, the quencher is selected from the group consisting of dabsyl, dabcyl, and black quenchers.

[0031] In some embodiments, identification of aptamers that bind to AAV capsids is performed by sequencing.

[0032] In some embodiments, sequencing includes performing high throughput sequencing or droplet sequencing.

[0033] In some embodiments, the targets of the aptamers in the aptamer library are known.

[0034] In some embodiments, it is not necessary to know the precise targets of the aptamers in the aptamer library.

[0035] In some embodiments, the AAV capsids are in solution prior to contacting with the aptamer library.

[0036] In some embodiments, the AAV capsids are immobilized on a support prior to contacting with the aptamer library.

[0037] In some embodiments, the method further comprises characterizing the 3D molecular surface features of additional AAV capsid(s).

[0038] The present disclosure also provides a method for characterizing the 3D molecular surface features of an AAV capsid, comprising:

[0039] a) contacting the AAV capsid with a DNA-encoded chemical library (DECL) comprising a pool of DNA-encoded chemical binders targeting one or more AAV capsids;

[0040] b) removing unbound DNA-encoded chemical binding agents;

[0041] c) eluting the bound DNA-encoded chemical binder;

[0042] d) identifying DNA-encoded chemical binders that bind to AAV capsids;

[0043] e) determining the presence and / or level of the identified DNA-encoded chemical binding agent; and

[0044] f) Characterizing the 3D molecular surface features of the AAV capsid based on the presence and / or levels of the identified DNA-encoded chemical binders.

[0045] In some embodiments, steps a)-c) are repeated 1, 2, 3 or more times.

[0046] In some embodiments, each DNA-encoded chemical binding agent in the DECL comprises:

[0047] a) a compound capable of binding to one or more targets on the AAV capsid;

[0048] b) DNA barcoding; and

[0049] c) Connector.

[0050] In some embodiments, the DNA barcode of the eluted DNA encoding the chemical binding agent is amplified by a PCR reaction.

[0051] In some embodiments, the DNA barcode sequence of the DNA-encoded chemical binding agent is about 5 bp to about 15 bp in length.

[0052] In some embodiments, the DNA barcode sequence of each DNA-encoded chemical binding agent is associated with the identity of the chemical binding agent.

[0053] In some embodiments, identification of DNA-encoded chemical binders is performed by sequencing of DNA barcode sequences.

[0054] In some embodiments, sequencing includes performing high-throughput sequencing, droplet sequencing, or single-cell sequencing.

[0055] In some embodiments, the target of the chemical binder encoded by the DNA in the DECL is known.

[0056] In some embodiments, it is not necessary to know the precise targets of the DNA-encoded chemical binders in the aptamer library.

[0057] In some embodiments, the AAV capsid is in solution prior to contacting with the DECL.

[0058] In some embodiments, the AAV capsid is immobilized on a support prior to contacting with the DECL.

[0059] In some embodiments, the linker is a cleavable linker.

[0060] In some embodiments, the method further comprises characterizing the 3D molecular surface features of additional AAV capsid(s).

[0061] The present disclosure also provides a method for characterizing the 3D molecular surface features of an AAV capsid, comprising:

[0062] a) contacting the AAV capsid with a DNA-encoded antibody library (DEAL) comprising a pool of DNA-encoded antibody binders that target one or more AAV capsids;

[0063] b) removing unbound DNA-encoded antibody binder;

[0064] c) eluting the bound DNA-encoded antibody binder;

[0065] d) identifying DNA-encoded antibody binders that bind to AAV capsids;

[0066] e) determining the presence and / or level of the identified DNA-encoded antibody binder; and

[0067] f) Characterizing the 3D molecular surface features of the AAV capsid based on the presence and / or levels of the identified DNA-encoded antibody binders.

[0068] In some embodiments, steps a)-c) are repeated 1, 2, 3 or more times.

[0069] In some embodiments, each DNA-encoded antibody binding agent in the DECL comprises:

[0070] a) an antibody or antigen-binding fragment thereof that is capable of binding to one or more targets on the AAV capsid;

[0071] b) DNA barcoding; and

[0072] c) Connector.

[0073] In some embodiments, the DNA barcode of the eluted DNA encoding the antibody binder is amplified by a PCR reaction.

[0074] In some embodiments, the DNA barcode sequence of the DNA-encoded antibody binder is about 5 bp to about 15 bp in length.

[0075] In some embodiments, identification of DNA-encoded antibody binders is performed by sequencing.

[0076] In some embodiments, sequencing includes performing high throughput sequencing or droplet sequencing.

[0077] In some embodiments, the target of the antibody binder encoded by the DNA in DEAL is known.

[0078] In some embodiments, it is not necessary to know the precise targets of the antibody binders encoded by the DNA in the DEAL library.

[0079] In some embodiments, the AAV capsid is in solution prior to contacting with DEAL.

[0080] In some embodiments, the AAV capsids are immobilized on a support prior to contacting with DEAL.

[0081] In some embodiments, the linker is a cleavable linker.

[0082] In some embodiments, the linker includes at least one nucleic acid molecule that includes an enzymatically cleavable sequence (CL).

[0083] In some embodiments, the method further comprises characterizing the 3D molecular surface features of additional AAV capsid(s).

[0084] The present disclosure also provides a method for enriching a binding library for characterizing the 3D molecular surface features of AAV capsids, comprising:

[0085] (a) contacting a pool of binding reagents with a first population of AAV capsids;

[0086] (b) Enriching a sub-pool of binders that bind to the first population of AAV capsids, thereby enriching the binding library for characterizing the 3D molecular surface features of AAV capsids.

[0087] In some embodiments, the method further comprises:

[0088] (c) contacting the subpool of binding agents that bind to the first population of AAV capsids with a second population of AAV capsids; and

[0089] (d) depleting the second sub-pool of binders that display affinity for the second population of AAV capsids, thereby selecting a population of binders that have preferential affinity for the first population of AAV capsids.

[0090] In some embodiments, the library of binding agents is an aptamer library, a DNA-encoded chemical library (DECL), or a DNA-encoded antibody library (DEAL).

[0091] In some embodiments, the AAV capsid or the first population of AAV capsids includes one or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVhu.37, AAVrh.8, AAVrh.10, AAVrh.39, AAV11, AAV12, and AAV13, and other variants derived from mutations, peptide insertions, or shuffling.

[0092] In some embodiments, the 3D molecular surface features are binding properties of the library.

[0093] In some embodiments, the binding characteristic is the number, sequence, and copy number of bound binding agents.

[0094] In some embodiments, the 3D molecular surface features of the AAV capsid indicate tropism properties and / or neutralization properties (e.g., the ability to evade neutralizing antibodies).

[0095] The present disclosure also provides kits for performing the methods of enriching the binding libraries described in the present disclosure.

[0096] Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. The present disclosure describes methods and materials for use in the present invention; other suitable methods and materials known in the art may also be used. The materials, methods and examples are illustrative only and not restrictive. All publications, patent applications, patents, sequences, database entries and other references mentioned in this disclosure are incorporated herein by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.

[0097] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0098] Figure 1A is a schematic representation of aptamers in a linear aptamer library.

[0099] Figure 1B is a schematic representation of aptamers in a circular aptamer library.

[0100] Figure 2A is a schematic representation of the enrichment of the aptamer library for the AAV sample (AAV Mix 01).

[0101] Figure 2B is a schematic representation of the enrichment of the aptamer library for AAV sample (AAV Mix 02).

[0102] Figure 2CExemplary raw data obtained from aptamer enrichment described in the present disclosure are shown.

[0103] Figure 3 Counts for the top 100 enriched aptamers from each round of enrichment described in this disclosure are shown.

[0104] Figure 4 Sequence composition signatures of the top 100 enriched aptamers from each round of enrichment are shown.

[0105] Figure 5 Counts for the top 500 enriched aptamers described in the present disclosure are shown.

[0106] Figure 6 The number of enriched aptamers from any round of enrichment of the linear aptamer library is shown.

[0107] Figure 7A-7B The difference in counts of enriched circular aptamers relative to two AAV samples (AAV Mix 01 and AAV Mix02) is shown. The y-axis shows the difference in counts (calculated by C2*C0 / C1^2, C0=1 / number of enriched aptamer sequences). C1 is the number of enriched aptamers in the first round of enrichment. C2 is the number of enriched aptamers in the second round of enrichment. The x-axis shows the DNA sequence IDs of shared aptamers between the enriched aptamer libraries for two different AAV samples, where the aptamer count is greater than 50.

[0108] Figure 7C-7D The difference in counts of enriched linear aptamers relative to two AAV samples (AAV Mix 01 and AAV Mix02) is shown. The y-axis shows the difference in counts (calculated by C2*C0 / C1^2, C0=1 / number of enriched aptamer sequences). C1 is the number of enriched aptamers in the first round of enrichment. C2 is the number of enriched aptamers in the second round of enrichment. The x-axis shows the DNA sequence IDs of shared aptamers between enriched aptamer libraries for two different AAV samples, where the aptamer count is greater than 50.

[0109] Figures 8A-8B The count distribution of the enriched aptamers in the linear aptamer library is shown.

[0110] Figures 9A-9B The count distribution of the enriched aptamers in the circular aptamer library is shown.

[0111] Fig.10 is a schematic representation of a DNA encoded chemical library (DECL).

[0112] Fig.11is a schematic illustration of the use of DECL to characterize the 3D molecular surface features of AAV capsids.

[0113] Fig.12 Schematic illustration of the conversion of the 3D molecular surface features of the AAV capsid into DECL space.

[0114] Fig.13 Schematic illustration of the use of DECL and DEAL combined with droplet-based sequencing to characterize the 3D molecular surface features of AAV capsids.

[0115] Fig.14 Example descriptions of commercially available DNA-encoded libraries are shown.

[0116] Fig.15 A Venn diagram of the enriched DECL chemical binders against four AAV samples is shown.

[0117] Figures 16A-16D Cluster analysis of enriched DECL chemical binders performed using principal component analysis (PCA) is shown. DETAILED DESCRIPTION

[0118] The present disclosure relates to methods for analyzing 3D molecular surface features of AAV (adeno-associated virus) capsid variants in solution or on a solid support using DNA-encoded libraries (DELs), such as DNA-encoded chemical libraries (DECLs) and DNA-encoded antibody libraries (DEALs), phage display libraries, DNA aptamer libraries (single-stranded and circular aptamers), RNA aptamer libraries (single-stranded and circular aptamers), or combinations thereof. More specifically, the present disclosure relates to compositions and methods using binding libraries that selectively bind to the surface of AAV capsid variants, either individually or in combination, to convert the 3D surface molecular features of the AAV capsid variants into binding properties, thereby depicting and mapping the 3D molecular surface features.

[0119] The methods described in the present disclosure provide methods for converting the 3D molecular surface feature space of AAV capsids into specific protein-DNA encoding molecules or protein-aptamer affinity interaction features defined by the combination of the detection library and the AAV sample. The methods described in the present disclosure may also include droplet and / or single cell-like sequencing of DNA sequence information encoded by the protein-DNA-encoding molecules or protein-aptamer complexes. The present disclosure provides means for functional annotation of AAV capsids and a visualization platform that helps recombinant DNA vector engineering improve gene delivery applications.

[0120] Adeno-associated virus

[0121] Adeno-associated virus (AAV) is a single-stranded DNA packaging virus of the Parvoviridae family and belongs to the genus Dependoparvovirus. AAV-based vectors are being developed and used as gene delivery biologics to treat a variety of monogenic diseases. Thirteen human and primate AAV serotypes and many genomic isolates have been described and classified into six clades AF or single clonal isolates. The virion of AAV consists of a non-enveloped capsid with an icosahedral symmetry of T=1 and They are assembled from 60 viral proteins (VPs) in a ratio of approximately 1:1:10: VP1 (≈82 kDa), VP2 (≈73 kDa), and VP3 (≈61 kDa). VPs have a common C-terminus that includes the entire VP3. Compared to VP3, VP1 and VP2 are extended at their N-termini with a shared ≈65 amino acid (aa) region in the case of VP1 (VP1u) and an additional ≈137 aa N-terminus of VP2. The N-terminal regions of VP1 and VP2 contain conserved elements required for AAV infectivity, such as the phospholipase A2 (PLA2) domain, the calcium binding domain, and the nuclear localization signal. Overall, the VP1 amino acid sequence identity of AAV serotypes varies between 57% and 99%.

[0122] The capsid structures of several natural human and primate AAV serotypes, AAV1-AAV6, AAV8, AAV9, AAVhu.37, AAVrh.8, AAVrh.10, and AAVrh.39, have been determined by X-ray crystallography and / or cryo-electron microscopy (cryo-EM). Regardless of the method used to determine the structure, only the amino acid sequence of VP3 is ordered, except for the first ≈15 amino acids. The VP3 structure consists of an antiparallel eight-stranded (βB to βI) β barrel motif, in which the BIDG sheet forms the inner surface of the capsid. Another strand, βA, is antiparallel to the βB strand. In addition, all AAVs conserve the α helix (αA) located between βC and βD. Between each β strand, a large loop is inserted, which is characterized by a high degree of sequence and structural variability between AAVs. These circles form the outer surface of the capsid and are named after the β strands flanking them. For example, the HI loop is flanked by βH and βI strands. The sequence variability of different AAVs causes the selective conformation of these rings, which causes the surface characteristics of the AAV serotype-specific capsid molecule. Through structural alignment, the 9 significantly different regions of these ring vertices are defined as variable regions (VR). Although the structure of VR is different, the overall capsid morphology is conservative. These include cylindrical channels on the 5-fold symmetry axis of the icosahedron, formed by the ring (VR-II), surrounded by a depression mostly outlined by the HI ring. The 5-fold channel is considered to be the pathway for genomic DNA packaging and VP1u externalization during endo / lysosomal transport after cell entry. On the 2-fold symmetry axis, the two sides of the depression are protrusions around the 3-fold symmetry axis, and the raised capsid region between the 2-fold axis and the 5-fold axis is called the 2 / 5-fold wall. The 3-fold region and the 2 / 5-fold wall have been identified as receptor binding sites for many AAV serotypes and as determinants of cell and tissue tropism. Cellular receptors include sialic acid, heparan sulfate proteoglycans (HSPG), terminal galactose, sulfated N-acetyllactosamine, AAVR, laminin, αvβ1 integrin, αvβ5 integrin, hepatocyte growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor. In addition to receptor binding, the surface of the capsid, including the 5-fold region, displays antigenic sites for antibodies generated by the host immune response.

[0123] In recent studies, the structures of AAV7, AAV11, AAV12, and AAV13 capsids were determined by cryo-EM in an effort to complete the available structures of defined AAV serotypes. The empty and genome-containing capsid structures of these four AAV serotypes were reconstructed at 2.54 to 3.5 mm in diameter. All density maps showed clear amino acid side chain density and displayed features of the AAV capsid, including a channel on the 5-fold axis, depressions on the 2-fold axis and around the 5-fold axis, and a protrusion around the 3-fold axis. Comparison of the empty (DNA-free) and complete (genome-packaged) capsid structures showed no structural differences in the VP monomers other than the ordered nucleotides at the previously described nucleotide (nt) binding pocket in the case of complete capsids and alternative side chain orientations. Significant structural differences were observed primarily at the 3-fold protrusion and 2 / 5-fold wall compared to AAV2, due to aa insertions or deletions and sequence differences. This characterization of the AAV7, AAV11, AAV12, and AAV13 structures completes the library for serotype determination.

[0124] Further details about the AAV capsid and its structure are known in the art and can be found in review articles such as Mietzsch et al., Viruses. 2021 Jan; 13(1): 101; Cotmore SF et al., J. Gen. Virol. 2019; 100: 367–368. doi: 10.1099 / jgv.0.001212; Wang D. et al., Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 2019; 18: 358–378; Gao G et al., J. Virol. 2004; 78: 6381–6388. doi: 10.1128 / JVI.78.12.6381-6388.2004; Mietzsch M., Twenty-five years of structuralparvovirology. Viruses. 2019; 11: 362; Snijder J. et al., Defining the stoichiometry and cargo load of viral and bacterial nanoparticles by orbitrap massspectrometry. phospholipase A2 domain required for virus infectivity. Pt 5 J. Gen. Virol. 2002; 83:973–978; Popa-Wagner R. et al., Impact of VP1-specific protein sequence motifs on adeno-associated virustype 2 intracellular trafficking and nuclear entry. J. Virol. 2012; 86:9163–9174; and Daya S. et al., Gene therapy using adeno-associated virusvectors.Clin.Microbiol.Rev.2008;21:583–593; each of which is incorporated herein by reference in its entirety. .

[0125] 3D molecular surface characteristics of AAV capsid

[0126] Adeno-associated virus (AAV) has become the vector of choice for many current gene therapy approaches. AAV is highly infective, but has a natural replication defect in the absence of a helper virus, and its genome is easy to manipulate. In order to generate a recombinant AAV (rAAV) vector, the viral gene is replaced with a transgenic expression cassette while retaining the flanking inverted terminal repeats (ITRs) required for encapsidation. The viral capsid protein for encapsidating the vector DNA is provided in trans, and the resulting rAAV is subsequently purified. To date, the safety of rAAV vectors has been well established in decades of research and more than 200 clinical trials. Many more upcoming research new drug applications are under review at different stages. AAV-mediated gene transfer benefits many individuals with genetic diseases by mediating long-term expression of transgenes. However, there are still some obstacles, such as pre-existing immunity to rAAV capsids and undesirable immune responses to transgenic products.

[0127] Different subtypes of AAV capsids can deliver DNA to a variety of cells and tissues, and the specific cells and tissues vary by subtype. This is due to the organization of the icosahedral-shaped capsid to form an envelope around the DNA payload and interact with specific molecules on the target cell via the spike structure protruding from the capsid surface. One challenge faced by many gene therapies is that the AAV virus is taken up by cells that should not be targeted. This reduces the efficiency of the virus at the intended target site and causes undesirable reactions in other cell and tissue types. These also include immune system cells and immune memory that can trigger an immune response, which prevents the therapeutic virus from being delivered a second time at a later time, if this is necessary.

[0128] Therefore, the present disclosure provides a method for characterizing the 3D molecular surface features of AAV capsids. The 3D molecular surface features used in the present disclosure refer to any structural, chemical and functional features (one or more) of the AAV capsid. For example, the 3D molecular surface features of the AAV capsid may include the components of the AAV capsid (e.g., the VP protein composition of the AAV capsid), the secondary or tertiary protein structure of the AAV capsid, the biophysical properties of the AAV capsid (e.g., its ability to bind receptors, small molecules or other proteins in vitro and in vivo), the viral tropism of AAV, and the antibody neutralization or immunogenicity characteristics of AAV. These 3D molecular surface features can be used to predict the immune response and delivery efficiency of different tissues and cells.

[0129] Pre-existing neutralizing antibodies against the AAV capsid have been found in a significant proportion of the population exposed to circulating wild-type AAV. These antibodies greatly reduce the transduction efficiency of rAAV and can prevent successful delivery of transgenes in these individuals. Therefore, antibody binding properties are important for the engineering of AAV capsids.

[0130] In some embodiments, the 3D molecular surface features of the AAV capsid are antibody binding properties of the AAV. In some embodiments, the 3D molecular surface features of the AAV capsid are indicative of the antibody binding preferences of the AAV.

[0131] Although rAAV vectors are traditionally considered non-immunogenic, immune responses can be generated to AAV itself and / or the transgene product. Post-translational modifications have recently been discovered on the rAAV capsid that may contribute to the undesirable immunogenicity seen in some gene therapy recipients.

[0132] When selecting the most appropriate rAAV serotype for gene delivery, viral tropism, or the ability to infect specific tissues or cell types, is a key factor to consider. The tropism of the virus is primarily determined by the rAAV capsid, and a variety of different capsid serotypes have been identified. When producing rAAV vectors in the laboratory, the AAV2 ITR genome is engineered to contain the transgene of interest, and the resulting recombinant genome is encapsulated in a preferred capsid. Depending on the desired target cell or tissue, different serotypes may be preferred. Another potential source of immunogenicity for rAAV-expressed transgenic products is related to off-target delivery. Unintentional transduction of antigen presenting cells (APCs) can result in presentation to the immune system and trigger an immune response.

[0133] In some embodiments, the 3D molecular surface characteristics of the AAV capsid are the viral tropism of the AAV. In some embodiments, the 3D molecular surface characteristics of the AAV capsid are indicative of the tropism of the AAV (eg, rAAV).

[0134] Although primarily used to treat monogenic diseases, rAAV-mediated gene transfer can also be used to deliver immunotherapeutics, such as monoclonal antibodies. Coding sequences for appropriately characterized protective / neutralizing antibodies against pathogens of interest can be delivered via rAAV, thereby aiming to prevent or treat infectious diseases and confer lasting immunity.

[0135] There is an ongoing immunological and molecular race between AAV and its human host. There is a need in the art for safer and more broadly applicable therapies.

[0136] In some embodiments, the methods described in the present disclosure characterize the 3D molecular surface features of a population of AAV capsids. In some embodiments, there are about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 types of AAV capsids in the population of AAV capsids. In some embodiments, the types of AAV capsids in the population are selected from serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVhu.37, AAVrh.8, AAVrh.10, AAVrh.39, AAV11, AAV12, and AAV13. In some embodiments, the AAV capsids in the population are wild-type AAV capsids. In some embodiments, one or more AAV capsids in the population include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 mutations in the capsid protein. In some embodiments, the mutation is a single point mutation. In some embodiments, the mutation is at multiple amino acid residues in the AAV capsid protein.

[0137] In some embodiments, the population of AAV capsids comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 10 20 In some embodiments, the population of AAV capsids comprises about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 1010 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 or 10 20 In some embodiments, the population of AAV capsids comprises about 1 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 2 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 3 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 4 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 5 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 6 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 7 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 8 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 9 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 10 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 11 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 12 to about 10 20In some embodiments, the population of AAV capsids comprises about 10 13 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 14 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 15 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 16 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 17 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 18 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 19 to about 10 20 In some embodiments, the population of AAV capsids comprises about 10 to about 10 10 In some embodiments, the population of AAV capsids comprises about 10 2 to about 10 10 In some embodiments, the population of AAV capsids comprises about 10 3 to about 10 10 In some embodiments, the population of AAV capsids comprises about 10 4 to about 10 10 In some embodiments, the population of AAV capsids comprises about 10 5 to about 10 10 In some embodiments, the population of AAV capsids comprises about 10 6 to about 10 10 In some embodiments, the population of AAV capsids comprises about 10 7 to about 10 10 In some embodiments, the population of AAV capsids comprises about 10 8 to about 10 10 In some embodiments, the population of AAV capsids comprises about 10 9 to about 10 10or more AAV capsids.

[0138] The methods described in the present disclosure (e.g., using aptamer libraries, DECL, DEAL and / or phage display libraries to characterize the 3D molecular surface characteristics of viral capsids) can be used to characterize the 3D molecular surface characteristics of any suitable viral particles, virus-like particles, self-assembling proteins for gene delivery purposes.

[0139] Characterization of the 3D molecular surface features of AAV capsids using aptamer libraries

[0140] Aptamers are nucleic acid species routinely selected in vitro by SELEX (systematic evolution of ligands by exponential enrichment). Since being introduced by Gold and Szostak groups (Tuerk and Gold, Science, vol.249, pp.505-510, (1990)), aptamers have been developed as molecular recognition elements to detect almost any target of interest, from small molecules to proteins and even cells and tissues. Aptamers are easy to regenerate at low cost by chemical synthesis. In addition, they have ideal storage characteristics and rarely or do not cause immunogenicity in biological environments. Their application in therapeutics and diagnostics has been significantly expanded. Recently, the lack of signal transduction properties inherent to aptamers has promoted the development of various strategies, which are used to transduce target binding events into signals that are easily measured in biotechnology and biomedical applications (see, for example, Navani and Li, Curr.Opin.Chem.Biol., vol.10, pp.272-281 (2006)).

[0141] Methods using fluorescent reporters have proven to be particularly useful in the generation of aptamer-based biosensors; these methods include single chromophore approaches (see, e.g., Jhaveri et al., J. Am. Chem. Soc., vol. 122, pp. 2469-2473 (2000)), aptamer beacon engineering (see, e.g., Hamaguchi et al., Anal. Biochem., vol. 294, pp. 126-131 (2001)), structural switching signals (see, e.g., Nutiu and Li, J. Am. Chem. Soc., vol. 125, pp. 4771-4778 (2003)), in situ labeling (see, e.g., Merino and Weeks, J. Am. Chem. Soc., vol. 125, pp. 12370-12371 (2003)), allosteric chimeras (see, e.g., Wu and Curran, Nucleic Acids Res., vol. 27, pp. 1512-1516 (1999)), dye staining methods (see, e.g., Li et al., Chem. Commun., pp. 73-75 (2007)), and fluorescent chemical sensors based on polymer conjugates (see, e.g., Ho and Leclerc, J. Am. Chem. Soc., vol. 126, pp. 1384-1387 (2004)). Although these systems generally generate signals in a stoichiometric manner, attempts have been made to amplify the signal by combining proximity ligation analysis (see, e.g., Fredriksson et al., Nature Biotechnol., vol. 20, pp. 473-477 (2002)) or exonuclease protection assays (see, e.g., Wang et al., Anal. Chem., vol. 76, pp. 5605-5610 (2004)). In addition, DNA-polymerase analysis incorporating molecular beacons has been used for amplification detection of recognition between aptamers and target small molecules (see, e.g., Shlyahovsky et al., J. Am. Chem. Soc., vol. 129, pp. 3814-3815 (2007)). Such technologies are a continuing need for developing simple and easy-to-apply aptamer-based methods that can facilitate accurate and specific biological analysis.

[0142] In one aspect, the present disclosure provides a method for characterizing the 3D molecular surface features of an AAV capsid, comprising: a) contacting an AAV capsid with a library of aptamers targeting one or more AAV capsids; b) removing unbound aptamers; c) eluting bound aptamers; d) identifying aptamers bound to the AAV capsid; e) determining the presence and / or level of the identified aptamers; and f) characterizing the 3D molecular surface features of the AAV capsid based on the presence and / or level of the identified aptamers.

[0143] In some embodiments, the enrichment of the aptamer library for the AAV sample (ie, the contacting, washing, and elution steps (steps ac)) is repeated 1, 2, 3, 4, 5, or more times.

[0144] The methods described in the present disclosure can be performed in any suitable solution or buffer. In some embodiments, the enrichment of the aptamer library for AAV samples is performed in DPBS buffer (e.g., 1.47mM KH2PO4, 8mM Na2HPO4, 138mM NaCl, 2.67mM KCl, 0.5mM MgCl2, 0.9mM CaCl2, pH 7.4). It will be readily understood by those of ordinary skill in the art that any other suitable buffer and reagent range in the buffer can be used for the methods described in the present disclosure.

[0145] In some embodiments, the enrichment of the aptamer library for the AAV sample is performed at room temperature. A person of ordinary skill in the art will readily appreciate that any other suitable temperature may be used to perform the methods described in the present disclosure.

[0146] In some embodiments, the eluted aptamers are amplified by polymerase chain reaction (PCR). In some embodiments, polymerase chain reaction (PCR) includes PCR-based methods, such as real-time polymerase chain reaction (RT-PCR), quantitative real-time polymerase chain reaction (Q-PCR / qPCR), etc., and electric field driven polymerase chain reaction (ePCR).

[0147] The aptamers in the library of the methods described in the present disclosure can be any suitable aptamers known in the art. In some embodiments, the aptamers in the aptamer library are linear aptamers. In some embodiments, the aptamers in the aptamer library are circular aptamers.

[0148] In some embodiments, each aptamer in the aptamer library includes at least one primer binding region and a random sequence. In some embodiments, the random sequence of the aptamer can be combined with one or more targets on the AAV capsid. In some embodiments, the length of the random sequence of the aptamer in the aptamer library is about 30bp to about 50bp. In some embodiments, the length of the random sequence of the aptamer in the aptamer library is about 30bp to about 40bp. In some embodiments, the length of the random sequence of the aptamer in the aptamer library is about 36 to about 40bp. In some embodiments, the method described in the present disclosure also includes excluding aptamer sequences (for example, before or after sequencing of the binding aptamer of elution).

[0149] In some embodiments, the length of the primer binding region of the aptamers in the aptamer library is about or at least 10 bp, about or at least 15 bp, about or at least 20 bp, about or at least 25 bp, about or at least 30 bp, about or at least 35 bp, about or at least 40 bp. In some embodiments, the length of the primer binding region of the aptamers in the aptamer library is about 20 bp.

[0150] The aptamers in the aptamer library can be double-stranded or single-stranded. In some embodiments, each aptamer in the aptamer library includes a double-stranded oligonucleotide sequence. In some embodiments, each aptamer in the aptamer library includes a single-stranded oligonucleotide sequence.

[0151] The aptamers or DEL chemical binders used in the methods described in the present disclosure can be directly or indirectly attached to a solid surface or substrate. The solid surface or substrate can be any physically separable solid to which the binder can be directly or indirectly attached, including but not limited to surfaces provided by microarrays and wells, particles such as beads, columns, optical fibers, wipes, glass and modified or functionalized glass, quartz, mica, diazotized membranes (paper or nylon), polyoxymethylene, cellulose, cellulose acetate, paper, ceramics, metals, metalloids, semiconductor materials, quantum dots, coated beads or particles, other chromatographic materials, magnetic particles; plastics (including acrylic resins, polystyrene, copolymers of styrene or other materials) , polypropylene, polyethylene, polybutylene, polyurethane, Teflon materials, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials, including silicon and modified silicon, carbon, metals, inorganic glass, plastics, ceramics, conductive polymers (including polymers such as polypyrrole and polyindole); micro- or nanostructured surfaces, such as nucleic acid tile arrays, nanotubes, nanowires or nanoparticle modified surfaces; or porous surfaces or gels, such as methacrylates, acrylamides, sugar polymers, cellulose, silicates or other fibers or strands of polymers. In addition, as is known in the art, the substrate can be coated with any number of materials, including polymers such as dextran, acrylamide, gelatin or agarose, using passive or chemically derived coatings. Such coatings can facilitate the use of the array with biological samples.

[0152] Aptamers or other useful binding agents may be conjugated to a detectable entity or label.

[0153] Suitable labels include, but are not limited to, magnetic labels, fluorescent groups, enzymes, chemiluminescent probes, metal particles, non-metallic colloidal particles, polymeric dye particles, pigment molecules, pigment particles, electrochemically active substances, semiconductor nanocrystals or other nanoparticles, including quantum dots or gold particles, fluorophores, quantum dots, or radioactive labels. Protein tags include green fluorescent protein (GFP) and its variants (e.g., cyan fluorescent protein and yellow fluorescent protein); and luminescent proteins such as luciferase, as described below. Radioactive labels include, but are not limited to, radioisotopes (radionuclides), such as 3 H. 11 C. 14 C. 18 F. 32 P. 35 S. 64 Cu, 68 Ga, 86 Y. 99 Tc, 111 In, 123 I. 124 I. 125 I. 131 I.133 Xe, 177 Lu, 211 At or 213 Bi. Fluorescent labels include, but are not limited to, rare earth chelates (e.g., europium chelates), rhodamine; fluorescein types include, but are not limited to, FITC, 5-carboxyfluorescein, 6-carboxyfluorescein; rhodamine types include, but are not limited to, TAMRA; dansyl; Lissamine; cyanines; phycoerythrin; Texas Red; Cy3, Cy5, dapoxyl, NBD, Cascade Yellow, dansyl, PyMPO, pyrene, 7-diethylaminocoumarin-3-carboxylic acid and other coumarin derivatives, Marina Blue TM 、Pacific Blue TM Cascade Blue TM , 2-Anthracenesulfonyl, PyMPO, 3,4,9,10-Perylene-tetracarboxylic acid, 2,7-Difluorofluorescein (Oregon Green TM 488-X), 5-carboxyfluorescein, Texas Red TM -X, Alexa Fluor 430, 5-carboxytetramethylrhodamine (5-TAMRA), 6-carboxytetramethylrhodamine (6-TAMRA), BODIPY FL, bimane and Alexa Fluor 350, 405, 488, 500, 514, 532, 546, 555, 568, 594, 610, 633, 647, 660, 680, 700 and 750, and their derivatives, among many others. See, e.g., "Handbook - A Guide to Fluorescent Probes and Labeling Technologies," Tenth Edition, available on the Internet at probes(dot)invitrogen(dot)com / handbook. The fluorescent label can be one or more of FAM, dRHO, 5-FAM, 6FAM, dR6G, JOE, HEX, VIC, TET, dTAMRA, TAMRA, NED, dROX, PET, BHQ, Gold540 and LIZ.

[0154] The aptamer can be labeled directly or indirectly using conventional techniques, for example, by attaching a label to the aptamer via biotin-streptavidin (e.g., synthesizing a biotinylated aptamer that is then capable of binding to a streptavidin molecule that is itself conjugated to a detectable label; a non-limiting example is streptavidin, phycoerythrin conjugate (SAPE). Chemical coupling methods using multi-step procedures include biotinylation, coupling of trinitrophenol (TNP) or digoxigenin, for example using succinimidyl esters of these compounds. Biotinylation can be accomplished, for example, using D-biotinyl-N-hydroxysuccinimide. The succinimidyl group reacts efficiently with amino groups at pH values ​​above 7, and preferably between about pH 8.0 and about pH 8.5. Alternatively, the aptamer is not labeled, but is subsequently contacted with a labeled secondary antibody after binding of the primary antibody to the antigen of interest.

[0155] Various enzyme-substrate labels can also be used in combination with the compositions or methods described in the present disclosure. Such enzymes generally catalyze chemical changes in chromogenic substrates that can be measured with various techniques. For example, the enzyme can catalyze the color change of a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme can change the fluorescence or chemiluminescence of a substrate. Examples of enzyme labels include luciferase (e.g., firefly luciferase and bacterial luciferase), luciferin, 2,3-dihydrophthalazinedione, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRP), alkaline phosphatase (AP), β-galactosidase, glucoamylase, lysozyme, sugar oxidase (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, etc. Examples of enzyme-substrate combinations include, but are not limited to, horseradish peroxidase (HRP) with catalase as a substrate, where the catalase oxidizes a dye precursor (e.g., o-phenylenediamine (OPD) or 3,3',5,5'-tetramethylbenzidine hydrochloride (TMB)); alkaline phosphatase with p-nitrophenyl phosphate as a chromogenic substrate; and β-D-galactosidase (β-D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl-β-D-galactosidase) or a fluorogenic substrate 4-methylumbelliferyl-β-D-galactosidase.

[0156] The aptamer (one or more) can be connected to a substrate, such as a planar substrate. Planar arrays generally contain addressable locations (e.g., pads, addresses, or micro-locations) of biomolecules in array form. The size of the array will depend on the composition and end use of the array. The array can contain from 2 to thousands of different molecules. In general, depending on the end use and manufacturing method of the array, the array includes 2 to as many as 100,000 or more molecules.

[0157] In some embodiments, each aptamer in the aptamer library includes a single-stranded DNA (Guard-DNA or G-DNA) that is complementary to a region of the DNA aptamer that includes a 5'-extension region.

[0158] In some embodiments, when the AAV capsid is contacted with the aptamer library, the single-stranded G-DNA molecule is released, and the identification of the binding agent comprises: contacting the mixture obtained in step a) with RNase H and a single-stranded RNA complementary to the G-DNA, wherein a fluorophore and a quencher are labeled at the 5' end and the 3' end of the single-stranded RNA, respectively; and measuring the fluorescence intensity of the mixture;

[0159] In some embodiments, the fluorophore is selected from the group consisting of fluorescein, tetramethylrhodamine, Cy5, Cy3, and Texas Red.

[0160] Any suitable quencher may be used in the methods described in the present disclosure. In some embodiments, the quencher is selected from the group consisting of dabsyl, dabcyl, and black quenchers.

[0161] In some embodiments, identification of the binder is performed by sequencing.

[0162] In some embodiments, the methods described in the present disclosure include identifying target-specific aptamer properties. In one embodiment, a pool of aptamers for an AAV sample is selected and compared with a reference sample (e.g., a non-AAV sample or a different AAV sample), and conventional sequencing techniques can be used to sequence aptamers in a subgroup that binds to a component in the AAV sample but not to a component (one or more) in the reference sample to identify the bound subgroup, thereby identifying the aptamer properties of a specific AAV sample. In this way, aptamer properties provide an individualized platform for characterizing the 3D molecular surface features of the AAV capsid in an AAV sample. In addition, by selecting a suitable reference or control sample, aptamer properties can provide a predictive model for an AAV sample (e.g., a population that includes an AAV capsid) to characterize additional test AAV samples.

[0163] In some embodiments, the pool of aptamers may include any number of desired sequences, for example, at least 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 1210 13 10 14 10 15 10 16 10 17 10 18 10 19 or at least 10 20 oligonucleotides. Steps (a)-(c) may be repeated to further hone the pool of aptamers. In one embodiment, these steps are repeated at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times.

[0164] Various sequencing, amplification and hybridization techniques can be used to identify eluted aptamers. For example, when using a large pool of oligonucleotides, oligonucleotide identification can be performed by high-throughput methods such as next-generation sequencing or via hybridization. In some embodiments, sequencing includes performing high-throughput sequencing, droplet sequencing or single-cell sequencing.

[0165] In some embodiments, the targets of the aptamers in the aptamer library are known. In some embodiments, the precise targets of the aptamers in the aptamer library do not have to be known.

[0166] The AAV capsid in the methods described in the present disclosure can be in any suitable form. In some embodiments, the AAV capsid is in solution before contacting the aptamer library. In some embodiments, the AAV capsid is immobilized on a support before contacting the aptamer library.

[0167] In some embodiments, the method also includes characterizing the 3D features of additional AAV capsids (one or more). The aptamer binding properties of an AAV sample can be used as a unique marker to identify the AAV sample and distinguish it from other AAV samples (one or more). In some embodiments, the aptamer binding properties include the sequence (one or more) of the binding aptamer for a specific AAV sample. In some embodiments, the aptamer binding properties include a copy of each bound aptamer for a specific AAV sample. In some embodiments, one or more parameters in the aptamer binding properties can be used to identify an AAV sample (e.g., a population of AAV capsids).

[0168] In some embodiments, the one or more 3D molecular surface features of the AAV capsid are comprised of about 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 910 10 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 or at least 10 20 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 20 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 15 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 10 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 5 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 4 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 3 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 2 The eluted aptamers were characterized.

[0169] In one aspect, the present disclosure provides a DNA aptamer library for detecting and characterizing the 3D molecular surface features of AAV capsid variants in a sample and suitable for the method of claim 1, comprising 1) a DNA duplex consisting of (a) a DNA aptamer library and (b) a single-stranded DNA (G-DNA), wherein the DNA aptamer library includes a sequence required for binding to the AAV capsid variant and a sequence extending from the 5' end of the target binding sequence, the single-stranded DNA (G-DNA) being complementary to a DNA aptamer region including the 5' extension region; 2) a single-stranded RNA complementary to the G-DNA, labeled with a fluorophore and a quencher; and 3) RNase H, wherein the length of the single-stranded RNA is not longer than the length of the single-stranded DNA.

[0170] In some embodiments, the fluorophore is selected from the group consisting of fluorescein, tetramethylrhodamine, Cy5, Cy3, and Texas Red.

[0171] In some embodiments, the quencher is selected from the group consisting of dabsyl, dabcyl and black quenchers. In some embodiments, the quencher is a fluorophore that acts as a fluorescence acceptor in a fluorescence resonance energy transfer (FRET) mechanism. In some embodiments, the AAV capsid variant particle is a protein complex comprising a capsid protein and a DNA genomic sequence.

[0172] In one aspect, the present disclosure provides a method for detecting 3D molecular surface features of AAV capsid variants using a DNA aptamer comprising a 5'-extension. One oligonucleotide covalently linked to a fluorophore is homologous to the 5'-extension, while another oligonucleotide covalently linked to a quencher is homologous to the target binding domain. Upon reaction with the target, the aptamer dissociates and generates a signal.

[0173] In some embodiments, the probe hybridizes to a specific sequence on the surface of an AAV capsid variant. The probe is then cleaved or cleaved and dissociated from the target. The dissociation of the probe fragments allows them to be detected. In some embodiments, a single-stranded RNA probe is used to delete a target DNA sequence. RNase H specifically degrades the RNA probe, forming a heteroduplex with the target DNA. The DNA can bind to another RNA probe, resulting in signal amplification.

[0174] In one aspect, the present disclosure provides a method for detecting the 3D molecular surface features of AAV capsid variants, which is amplified by amplifying the fluorescent signal generated when a DNA aptamer binds to the 3D molecular surface features of the AAV capsid variant in the presence of other molecules in the sample. The method comprises the following steps: 1) forming a DNA duplex consisting of: (a) a DNA aptamer (5'Ex_aptamer) comprising a sequence required for target binding and a sequence extending from the 5' end of the target binding sequence, and (b) a single-stranded DNA (Guard-DNA or G-DNA) complementary to the DNA aptamer region including the 5'-extension region; 2) mixing a sample containing AAV capsid variant particles with the DNA duplex of step 1), wherein the single-stranded G-DNA molecule is released; 3) mixing the mixture obtained in step 2) with RNase H and a single-stranded RNA (F-RNA-Q) complementary to G-DNA, wherein the fluorophore and the quencher are labeled at the 5' end and 3' end of the single-stranded RNA, respectively; and 4) measuring the fluorescence intensity of the mixture obtained in step 3).

[0175] In one aspect, the present disclosure provides a library for detecting 3D molecular surface features of AAV capsid variants in a sample and suitable for the method provided by the present disclosure. The library includes: 1) a DNA duplex, the DNA duplex is composed of (a) a DNA aptamer and (b) a single-stranded DNA (G-DNA), the DNA aptamer includes a sequence required for target binding and a sequence extending from the 5'-end of the target binding sequence, and the single-stranded DNA (G-DNA) is complementary to the DNA aptamer region including the 5'-extension region; 2) a single-stranded RNA complementary to the G-DNA, labeled with a fluorophore and a quencher; and 3) RNase H, and wherein the length of the single-stranded RNA is not longer than the length of the single-stranded DNA.

[0176] In some embodiments, a fluorescence intensity assay-based biosensor is used to measure the 3D molecular surface characteristics of AAV capsid variants in a sample.

[0177] The DNA aptamer of step 1) is a molecule having an extension sequence at the 5' end of the established aptamer (5'Ex_aptamer). The G-DNA in this embodiment is a single-stranded DNA molecule complementary to the DNA aptamer region including the 5'-extension region. The established aptamer is an aptamer that combines the 3D molecular surface features of the AAV capsid variant. The DNA duplex consisting of the DNA aptamer and the G-DNA can be formed by heating an aqueous solution containing the DNA aptamer and the G-DNA and slowly cooling at room temperature.

[0178] The AAV capsid variant particle of step 2) can be a protein complex including capsid protein and DNA genome sequence.

[0179] In some embodiments, the F-RNA-Q of step 3) is a RNA sequence having a fluorophore attached to its 5' end and a quencher attached to its 3' end. In some embodiments, the fluorophore is a conventional fluorescent material, such as fluorescein, tetramethylrhodamine, Cy5, Cy3 and Texas Red. In a preferred embodiment, the quencher can be a conventional quencher, such as dabsyl, dabcyl and black quenchers. The quencher can be another fluorophore as a fluorescent acceptor in a fluorescence resonance energy transfer (FRET) mechanism. Any more fluorophores and fluorescence quenchers known to those skilled in the relevant art can be used in the present invention.

[0180] In some embodiments, the RNase H of this embodiment is an enzyme that recognizes RNA / DNA double strands and degrades only the RNA portion of the double strands, but does not degrade single-stranded RNA. In the present disclosure, RNase H is used to degrade F-RNA-Q of F-RNA-Q / G-DNA double strands.

[0181] The DNA aptamer, G-DNA, F-RNA-Q, and RNase H used in the present disclosure may be commercially available.

[0182] In some embodiments, fluorescence intensity can be measured by a fluorometer known to those skilled in the relevant art, such as a ternary multimode detector, Wal-lac / Victor fluorescence, and Perkin-Elmer LB50B luminescence spectrometer.

[0183] The method of the present invention for detecting the 3D molecular surface characteristics of AAV capsid variants in a sample will be explained in more detail below.

[0184] In step 2), in the presence of the 3D molecular surface features of the AAV capsid variant, the partially double-stranded structure containing the 5'-end adapter complex preferably forms a protein-5'-end adapter complex; this causes the release of the single-stranded G-DNA molecule. In step 3), the biosensor system of this embodiment includes a single-stranded RNA probe F-RNA-Q, which has a fluorophore (F) attached at the 5' end. The intensity of the fluorophore is completely reduced by the quencher (Q) at the 3'-end. Then an RNA-DNA duplex is formed because the sequence of F-RNA-Q is complementary to the released G-DNA. The RNA-DNA duplex (wherein the fluorescence is quenched) is degraded by RNase H; this causes the separation of the fluorophore-containing RNA fragment from the quencher and is used to generate a fluorescent signal. If the AAV capsid variant particles are not present in the sample, no fluorescent signal is generated because the DNA aptamer is still bound to the G-DNA and cannot form an RNA-DNA duplex with F-RNA-Q. Since degradation of F-RNA-Q by RNase H does not destroy G-DNA, it can undergo duplex recombination with another F-RNA-Q molecule. The cycle of RNA-DNA duplex formation and subsequent RNase H digestion produces a mechanism for fluorescence signal amplification.

[0185] In addition, the method described in the present disclosure can be used to quantitatively analyze the 3D molecular surface features of AAV capsid variants, because the intensity of the fluorescent signal increases in proportion to the amount of AAV capsid variant particles. At the same time, if F-RNA-Q is much longer than G-DNA, G-DNA and F-RNA-Q can form a double strand, thereby inducing the catalytic action of RNase H and generating a false positive signal even when AAV capsid variant particles are not present in the sample. Therefore, the length of the single-stranded RNA is not longer than the length of G-DNA. When the amount of G-DNA is higher than the amount of DNA aptamer, the excess G-DNA remaining after binding to the DNA aptamer can bind to F-RNA-Q, and RNase H can be activated to generate a false positive signal.

[0186] Therefore, in the method of the present invention, the DNA aptamer and the G-DNA are preferably used in the same amount. Since the disclosed method is performed in a homogeneous solution, it is more convenient compared to ELISA (enzyme-linked immunosorbent assay) performed with an additional washing step.

[0187] In some embodiments, due to the high selectivity of DNA aptamers for AAV capsid variant particles, amplification of the fluorescent signal will not occur unless the target protein is present in the sample. In conventional chemometric detection methods, the detectable amount of the 3D molecular surface features of the AAV capsid variant varies according to the binding strength of the AAV capsid variant particles to the aptamer. In contrast, even when the concentration of the AAV capsid variant particles is lower than the dissociation constant of the AAV capsid variant particle-aptamer complex, a very small amount of 3D molecular surface features of the AAV capsid variant can be detected by using the signal amplification method of the present invention. Fluorescence amplification is obtained by the degradation cycle of F-RNA-Q by RNase H, which is triggered by a small amount of G-DNA released from the DNA aptamer when binding to the AAV capsid variant particles. For example, by using the present invention, thrombin at a concentration of 10nM can be easily detected, which is much less than the dissociation constant (~100nM) of the aptamer-thrombin complex. The 3D molecular surface features of the AAV capsid variant can be detected very quickly using the method described in the present disclosure.

[0188] The library described in the present disclosure for detecting the 3D molecular surface features of AAV capsid variants in a sample is suitable for the method provided by the present disclosure, and characteristically includes: 1) a DNA duplex, which is composed of (a) a DNA aptamer and (b) a single-stranded DNA, wherein the DNA aptamer includes a sequence required for target binding and a sequence extending from the 5' end of the target binding sequence, and the single-stranded DNA is complementary to the DNA aptamer region including the 5' extension region; 2) a single-stranded RNA complementary to the G-DNA, labeled with a fluorophore and a quencher; and 3) RNase H, and wherein the length of the single-stranded RNA is not longer than the length of the single-stranded DNA.

[0189] The AAV capsid variant particle can be a protein complex including capsid protein and DNA genomic sequence.

[0190] The interaction of DNA aptamers with any AAV capsid variant can be examined using droplet and / or single-cell sequencing technologies. Droplet and / or single-cell sequencing technologies allow large numbers of individual AAV-aptamer complexes to be sequenced with high sequencing accuracy.

[0191] Characterizing the 3D molecular surface features of AAV capsids using a DNA-encoded chemical library

[0192] DNA-encoded libraries (DELs) are collections of small molecules covalently linked to DNA, with unique information about the identity and structure of each library member. Small molecules are typically prepared by combinatorial assembly of smaller building blocks, and DELs allow for the rapid and simultaneous screening of hundreds of billions of small molecule compounds against protein targets of interest. DELs are used in drug discovery projects and provide tools for the detection and characterization of biological features.

[0193] As used in the present disclosure, DECL refers to a library of chemical binding agents comprising multiple DNA encodings. It will be appreciated by those of ordinary skill in the art that any suitable small molecule can be used as a DNA-encoded chemical binding agent to construct a DNA-encoded chemical library. For example, a detailed description of the DECL structure is disclosed in PCT Publication No. WO 2009 / 077173 A2, the entire contents of which are incorporated into the present disclosure.

[0194] In one aspect, the present disclosure provides a method for characterizing the 3D molecular surface features of AAV capsids, comprising: a) contacting the AAV capsids with a DNA-encoded chemical library (DECL), which includes a pool of DNA-encoded chemical binders that target one or more AAV capsids; b) removing unbound DNA-encoded chemical binders; c) eluting bound DNA-encoded chemical binders; d) identifying the DNA-encoded chemical binders bound to the AAV capsids; e) determining the presence and / or level of the identified DNA-encoded chemical binders; and f) characterizing the 3D molecular surface features of the AAV capsids based on the presence and / or level of the identified DNA-encoded chemical binders.

[0195] In some embodiments, DECL enrichment (eg, contacting, washing, and elution steps (steps ac)) for an AAV sample is repeated 1, 2, 3, 4, 5, or more times.

[0196] The methods described in the present disclosure can be performed in any suitable solution or buffer. In some embodiments, the enrichment of the aptamer library for AAV samples is performed in DPBS buffer (e.g., 1.47mM KH2PO4, 8mM Na2HPO4, 138mM NaCl, 2.67mM KCl, 0.5mM MgCl2, 0.9mM CaCl2, pH 7.4). Those of ordinary skill in the art will readily appreciate that any other suitable buffer and reagent range in the buffer can be used for the methods described in the present disclosure.

[0197] In some embodiments, the enrichment of DECL relative to the AAV sample is performed at room temperature. One of ordinary skill in the art will readily appreciate that any other suitable temperature may be used to perform the methods described in the present disclosure.

[0198] In some embodiments, the DNA barcode of the eluted DNA-encoded chemical binding agent is amplified by a PCR reaction. In some embodiments, the polymerase chain reaction (PCR) includes PCR-based methods such as real-time polymerase chain reaction (RT-PCR), quantitative real-time polymerase chain reaction (Q-PCR / qPCR), etc., and electric field driven polymerase chain reaction (ePCR).

[0199] In some embodiments, each DNA-encoded chemical binder in the DECL includes: a) a compound capable of binding to one or more targets on the AAV capsid; b) a DNA barcode; and c) a linker.

[0200] In some embodiments, the DNA barcode sequence of the DNA encoded chemical binding agent is about 5 bp to about 40 bp. In some embodiments, the DNA barcode sequence of the DNA encoded chemical binding agent is about 5 bp to about 30 bp. In some embodiments, the DNA barcode sequence of the DNA encoded chemical binding agent is about 5 bp to about 20 bp. In some embodiments, the length of the DNA barcode sequence of the DNA encoded chemical binding agent is about 5 bp to about 15 bp. In some embodiments, the length of the DNA barcode sequence of the DNA encoded chemical binder is about or at least 5bp, 6bp, 7bp, 8bp, 9bp, 10bp, 11bp, 12bp, 13bp, 14bp, 15bp, 16bp, 17bp, 18bp, 19bp, 20bp, 21bp, 22bp, 23bp, 24bp, 25bp, 26bp, 27bp, 28bp, 29bp, 30bp, 31bp, 32bp, 33bp, 34bp, 35bp, 36bp, 37bp, 38bp, 39bp, 40bp or more than 40bp.

[0201] In some embodiments, identification of DNA-encoded chemical binders is performed by sequencing of DNA barcode sequences. In some embodiments, sequencing includes performing high-throughput sequencing, droplet sequencing, or single-cell sequencing. Any other suitable sequencing technology described in the present disclosure and known in the art can be used to sequence the barcode sequences.

[0202] In some embodiments, the targets of the chemical binders encoded by the DNA in the DECL are known. In some embodiments, the precise targets of the chemical binders encoded by the DNA in the DECL library do not have to be known.

[0203] The AAV capsid in the methods described in the present disclosure can be in any suitable form. In some embodiments, the AAV capsid is in solution before contacting with the DECL. In some embodiments, the AAV capsid is fixed on a support before contacting with the DECL.

[0204] In some embodiments, the method also includes characterizing the 3D features of additional AAV capsids (one or more). The DECL binding properties of an AAV sample can be used as a unique marker to identify an AAV sample and distinguish it from other AAV samples (one or more). In some embodiments, the DECL binding properties include the sequence (one or more) of the chemical binding agent encoded by the DNA for the binding of a specific AAV sample. In some embodiments, the DECL binding properties include a copy of the chemical binding agent encoded by the DNA for each binding of a specific AAV sample. In some embodiments, one or more parameters in the DECL binding properties can be used to identify an AAV sample (e.g., a population of AAV capsids).

[0205] Any suitable compound can be used in the DNA-encoded chemical binding agents described in the present disclosure. In some embodiments, the chemical compound is a small molecule. In some embodiments, the small molecule is capable of binding to one or more targets on the surface of the AAV capsid.

[0206] Any suitable linker can be used for DECL described in the present disclosure. In some embodiments, the linker is a cleavable linker. The linker can be any part that performs the function of effectively connecting a chemical part to a DNA part.

[0207] The linker can vary in structure and length and has at least two features: (1) an operable link to the compound and (2) an operable link to the DNA portion. Since the nature of the chemical link is varied, any of a variety of chemicals can be used to achieve the indicated operable link to the compound and the DNA barcode. The size of the linker portion can vary greatly in terms of the length between the chemical portion and the DNA portion. In some embodiments, the link does not exceed a length sufficient to provide the indicated linking function. Thus, in some embodiments, the chain length of the linker is at least 1 to about 20 atoms.

[0208] Typical linkers can be amino modifiers (such as 3'-amino modifier C3, 3'-amino modifier C6 dC, 3'-amino modifier C6 dT, 3'-amino modifier C7, 3'-PT-amino modifier C3, 3'-PT-amino modifier C6, 5'-amino-dT-CE, 5'-amino modifier 5, 5'-amino modifier C12, 5'-amino modifier C3, 5'-amino modifier C6, amino modifier C2 dT, amino modifier C6 dA, amino modifier C6 dC, amino modifier C6 dG, amino modifier C6dT, amino modifier C6-U, 5'-amino modifier C12), thiol modifiers (e.g. 3'-thiol modifier C3 S-S1 5'-thiol modifier C6, 3'-C6-thiol modifier SS, 3'-C6 thiol modifier, 5'-C6 thiol modifier SS, 5'-C6 thiol modifier), carboxyl modifiers (e.g. 3 1 -carboxylate photolabile C6, 5'-carboxyl modifier C10, carboxyl-dT), or an aldehyde modifier (eg, 5'-aldehyde modifier C2). Other suitable linkers are known in the art.

[0209] DNA display of combinatorial small molecule libraries relies on multi-step, split and pool synthesis of the library, combined with enzymatic addition of DNA tags encoding the synthesis steps and the building blocks used. Typically several (e.g., 3 or 4) synthesis steps are performed and encoded, these steps include diversity positions, such as those formed by coupling building blocks with, for example, amine or carboxylate functional groups to a chemical scaffold that displays the attached building blocks in a defined orientation. An example of a scaffold (one or more) commonly used in combinatorial libraries is a triazine moiety, which can be orthogonally derivatized at three positions of its ring structure.

[0210] The process of library formation can be time consuming, the products are often inefficient to purify, and as a result, unknown reactions can occur, creating unwanted and / or unknown molecules attached to the DNA. The end result of screening and sequencing hits from the library is that massively parallel sequencing must be employed, as both DNA have inherent "noise" attached to unintended molecules (e.g., unreacted or byproducts) or to molecules that are mislabeled.

[0211] In some embodiments, the starting oligonucleotides for construction of the small molecule library comprise a primer binding region for polymerase amplification (eg, PCR) in the form of a covalently closed double-stranded oligonucleotide.

[0212] Combinatorial chemistry, for example, involves splitting and mixing chemistry, and can be used to synthesize a large number of compounds. Compounds prepared in this manner can be used in the field of medicinal chemistry, where compounds can be screened for various biochemical activities. These activities include binding to one or more proteins, where the proteins are known when the screening test is performed. Alternatively, the protein bound by the test compound can be identified only after the binding event is detected.

[0213] The detailed method of constructing DECL is disclosed in, for example, PCT Publication No. WO 2009 / 077173 A2, the entire contents of which are incorporated into the present disclosure.

[0214] In one aspect, the present disclosure provides methods for generating DNA-encoded chemical libraries for detecting and characterizing 3D molecular surface features of AAV capsids. In some embodiments, the method comprises: a) reacting a first functional group of a bifunctional linker with a first chemical building block, wherein the bifunctional linker has a single functional group that reacts with a chemical building block and a single functional group that reacts with a nucleotide, a nucleotide analog, a nucleoside, or a nucleoside analog; b) reacting a second functional group of the bifunctional linker with a single-stranded hairpin oligonucleotide comprising (i) a self-complementary region and (ii) a single-stranded loop comprising at least one natural nucleoside or nucleoside analog, thereby forming a conjugate; c) reacting the second chemical building block with the first chemical building block of the conjugate under conditions suitable for forming a covalent bond between the first chemical building block and the second chemical building block of the conjugate; and d) attaching a first oligonucleotide tag to the single-stranded hairpin oligonucleotide of the conjugate, wherein the oligonucleotide tag comprises a region encoding the identity of the first chemical building block and / or the identity of the second chemical building block, thereby forming a DNA-encoded chemical entity, wherein steps (a) and (b) and / or steps (c) and (d) may be performed in any order.

[0215] In some embodiments, the ligating of step (d) comprises non-enzymatic ligation.

[0216] In some embodiments, the oligonucleotide tag of step (d) comprises a fluorescent tag or a biotin label.

[0217] In some embodiments, the single-stranded hairpin oligonucleotide of step (b) includes a region encoding the identity of the first building block. In some embodiments, the single-stranded hairpin oligonucleotide of step (b) and / or the oligonucleotide tag of step (d) are modified to increase the solubility of the DNA-encoded chemical binder under organic conditions. In some embodiments, the single-stranded loop of the hairpin oligonucleotide includes a sequence that can serve as a primer binding region for amplification. In some embodiments, the single-stranded hairpin oligonucleotide of step (b) includes a T or C nucleotide that includes a fatty chain at the C5 position. In some embodiments, the single-stranded hairpin oligonucleotide of step (b) includes azobenzene.

[0218] In some embodiments, the bifunctional linker is modified to increase the solubility of the DNA-encoded chemical binder under organic conditions. In some embodiments, the bifunctional linker includes one or more alkyl chains, polyethylene glycol units, positively charged branched substances, or hydrophobic ring structures. In some embodiments, the bifunctional linker includes about 10 to about 50 polyethylene glycol units. In some embodiments, the bifunctional linker includes about 12 to about 45 polyethylene glycol units.

[0219] In some embodiments, the oligonucleotide tag of step (d) comprises a region encoding the identity of the first chemical building block. In some embodiments, the oligonucleotide tag of step (d) comprises a region encoding the identity of the second chemical building block.

[0220] In some embodiments, suitable conditions for step (c) include an organic solvent.

[0221] In some embodiments, the bifunctional linker is attached to the 5' end of the single stranded hairpin oligonucleotide of step (b); the bifunctional linker is embedded in the single stranded hairpin oligonucleotide of step (b); or the bifunctional linker is located in the middle of the single stranded hairpin oligonucleotide of step (b).

[0222] In some embodiments, the bifunctional linker is attached to the 5' end of the single-stranded hairpin oligonucleotide of step (b). In some embodiments, the bifunctional linker is embedded in the single-stranded hairpin oligonucleotide of step (b). In some embodiments, the bifunctional linker is located in the middle of the single-stranded hairpin oligonucleotide of step (b).

[0223] In some embodiments, the oligonucleotide tag of step (d) comprises a T or C nucleotide including an aliphatic chain at the C5 position.

[0224] In some embodiments, the method further comprises attaching a second oligonucleotide tag encoding the identity of a second chemical building block to the first oligonucleotide tag.

[0225] In some embodiments, the method further comprises: (e) reacting the third chemical building block with the first chemical building block or the second chemical building block. In some embodiments, the method further comprises: (f) attaching a third oligonucleotide tag to the second oligonucleotide tag, wherein the third oligonucleotide tag encodes the identity of the third chemical building block, wherein steps (e) and (f) can be performed in any order.

[0226] In some embodiments, the method further comprises: (e) reacting one or more additional chemical building blocks with the chemical building blocks of the conjugate. In some embodiments, the method further comprises: (f) attaching one or more oligonucleotide tags to the oligonucleotide tag of the conjugate, wherein each oligonucleotide tag encodes the identity of one of the one or more additional building blocks, wherein steps (e) and (f) can be performed in any order.

[0227] In some embodiments, the method produces a plurality of DNA-encoded chemical binding agents.

[0228] The pool of DNA-encoded chemical binders described in the present disclosure may include any suitable number of DNA-encoded chemical binders. In some embodiments, the pool of DNA-encoded chemical binders includes at least 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 Types, at least 10 20 One or more different DNA-encoded chemical binding agents.

[0229] In some embodiments, in the methods described herein, the one or more 3D molecular surface features of the AAV capsid are comprised of about 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 109 10 10 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 or at least 10 20 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 20 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 15 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 10 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 5 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 4 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 3 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 2 A DNA-encoded chemical binder was characterized.

[0230] Characterization of the 3D molecular surface features of AAV capsids using DNA-encoded antibody libraries (DEAL)

[0231] Antibody-based reactions are widely used in disease diagnosis. For example, enzyme-linked immunosorbent assay (ELISA), western blot, and indirect fluorescent antibody assay are very useful for identifying single target proteins. Rapid and simultaneous screening of samples for the presence of multiple antibodies is beneficial in both research and clinical applications. The polymerase chain reaction (PCR) and other forms of target amplification have led to rapid progress in the development of powerful tools for detecting and quantifying DNA targets of interest. The development of comparable target amplification methods for proteins can significantly improve methods for detecting and quantifying targets such as AAV capsids.

[0232] In one aspect, the present disclosure provides a method for characterizing the 3D molecular surface features of AAV capsids, comprising: a) contacting the AAV capsids with a DNA-encoded antibody library (DEAL), the antibody library comprising a pool of DNA-encoded antibody binders that target one or more AAV capsids; b) removing unbound DNA-encoded antibody binders; c) eluting bound DNA-encoded antibody binders; d) identifying DNA-encoded antibody binders bound to the AAV capsids; e) determining the presence and / or level of the identified DNA-encoded antibody binders; and f) characterizing the 3D molecular surface features of the AAV capsids based on the presence and / or level of the identified DNA-encoded antibody binders.

[0233] In some embodiments, DEAL enrichment (ie, contacting, washing, and elution steps (steps ac)) for an AAV sample is repeated 1, 2, 3, 4, 5, or more times.

[0234] The methods described in the present disclosure can be performed in any suitable solution or buffer. In some embodiments, the enrichment of the aptamer library for AAV samples is performed in DPBS buffer (e.g., 1.47mM KH2PO4, 8mM Na2HPO4, 138mM NaCl, 2.67mM KCl, 0.5mM MgCl2, 0.9mM CaCl2, pH 7.4). Those of ordinary skill in the art will readily appreciate that any other suitable buffer and reagent range in the buffer can be used for the methods described in the present disclosure.

[0235] In some embodiments, DEAL enrichment for AAV samples is performed at room temperature. One of ordinary skill in the art will readily appreciate that any other suitable temperature may be used to perform the methods described in the present disclosure.

[0236] In some embodiments, each DNA-encoded antibody binder in a DEAL comprises: a) an antibody or antigen-binding fragment thereof capable of binding to one or more targets on an AAV capsid; b) a DNA barcode; and c) a linker.

[0237] In some embodiments, the DNA barcode of the eluted DNA encoding the antibody binder is amplified by a PCR reaction. In some embodiments, the polymerase chain reaction (PCR) includes PCR-based methods such as real-time polymerase chain reaction (RT-PCR), quantitative real-time polymerase chain reaction (Q-PCR / qPCR), etc., and electric field driven polymerase chain reaction (ePCR).

[0238] In some embodiments, the DNA barcode sequence of the DNA-encoded antibody binder is about 5 bp to about 40 bp. In some embodiments, the DNA barcode sequence of the DNA-encoded antibody binder is about 5 bp to about 30 bp. In some embodiments, the DNA barcode sequence of the DNA-encoded antibody binder is about 5 bp to about 20 bp. In some embodiments, the length of the DNA barcode sequence of the DNA-encoded antibody binder is about 5 bp to about 15 bp. In some embodiments, the length of the DNA barcode sequence of the DNA encoded antibody binder is about 5bp, 6bp, 7bp, 8bp, 9bp, 10bp, 11bp, 12bp, 13bp, 14bp, 15bp, 16bp, 17bp, 18bp, 19bp, 20bp, 21bp, 22bp, 23bp, 24bp, 25bp, 26bp, 27bp, 28bp, 29bp, 30bp, 31bp, 32bp, 33bp, 34bp, 35bp, 36bp, 37bp, 38bp, 39bp, 40bp or longer.

[0239] In some embodiments, identification of DNA-encoded antibody binders is performed by sequencing of DNA barcode sequences. In some embodiments, sequencing includes performing high-throughput sequencing, droplet sequencing, or single-cell sequencing. Any other suitable sequencing technology described in this disclosure and known in the art can be used to sequence the barcode sequences.

[0240] In some embodiments, the target of the antibody binder encoded by the DNA in the DEAL is known. In some embodiments, the precise target of the antibody binder encoded by the DNA in the DEAL library does not have to be known.

[0241] The AAV capsid in the methods described in the present disclosure can be in any suitable form. In some embodiments, the AAV capsid is in solution before contacting with DEAL. In some embodiments, the AAV capsid is immobilized on a support before contacting with DEAL.

[0242] In some embodiments, the method further comprises characterizing the 3D features of the additional AAV capsid (one or more). The DEAL binding properties of the AAV sample can be used as a unique marker to identify the AAV sample and distinguish it from other AAV samples (one or more). In some embodiments, the DEAL binding properties include the sequence (one or more) of the DNA-encoded antibody binder for the binding of a specific AAV sample. In some embodiments, the DEAL binding properties include a copy of the DNA-encoded antibody binder for each binding of a specific AAV sample. In some embodiments, one or more parameters in the DEAL binding properties can be used to identify the AAV sample (e.g., a population of AAV capsids).

[0243] The pool of DNA-encoded antibody binding agents described in the present disclosure may include any suitable number of DNA-encoded antibody binding agents. In some embodiments, the pool of DNA-encoded antibody binding agents includes at least 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 Types, at least 10 20 One or more different DNA-encoded antibody binding agents.

[0244] In some embodiments, in the methods described herein, the one or more 3D molecular surface features of the AAV capsid are composed of about or at least 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 1015 10 16 10 17 10 18 10 19 Species or 10 20 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 20 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 15 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 10 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 5 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 4 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 3 In some embodiments, in the methods described herein, one or more 3D molecular surface features of the AAV capsid range from about 10 to about 10 2 A DNA-encoded antibody binder is characterized.

[0245] Any suitable linker described in the present disclosure can be used in the DEAL described in the present disclosure. In some embodiments, the linker is a cleavable linker. The linker can be any part that performs the function of operably linking the antibody or antigen-binding fragment thereof to the DNA barcode.

[0246] The linker can vary in structure and length and has at least two features: (1) an operable link to the antibody or antigen-binding fragment thereof, and (2) an operable link to the DNA barcode. Since the nature of the chemical link is diverse, any of a variety of chemicals can be used to achieve the indicated operable link to the compound and the DNA barcode. The size of the linker portion can vary greatly in terms of the length between the antibody or antigen-binding fragment and the DNA barcode. In some embodiments, the link does not exceed a length sufficient to provide the indicated linking function. Thus, in some embodiments, the chain length of the linker is at least 1 to about 20 atoms.

[0247] The term "antibody" is used in the present disclosure to refer to any antibody-like molecule having an antigen binding region, and the term includes antibody fragments that include an antigen binding domain, such as Fab', Fab, F(ab')2, single domain antibodies (DAB or VHH), TandAbs dimers, Fv, scFv (single chain Fv), dsFv, ds-scFv, Fd, linear antibodies, miniantibodies, diabodies, bispecific antibody fragments, diabodies, triabodies (scFv-Fab fusion, bispecific or trispecific antibodies, respectively); sc-diabodies; kappa (lambda) bodies (scFv-CL fusions); DVD-Ig (dual variable domain antibodies, bispecific formats); SIP (small immune protein, a mini antibody); SMIP ("small modular immunodrug" scFv-Fc dimer; DART (ds-stable diabody "dual targeting"); small antibody mimetics including one or more CDRs, etc. The techniques for preparing and using various antibody-based constructs and fragments are well known in the art.

[0248] In some embodiments, the antibody is a monoclonal antibody. In order to prepare the monoclonal antibody that can be used in the present invention, mice or other suitable host animals are immunized with the antigen form of interest at suitable time intervals (e.g., twice a week, twice a week, twice a month, or once a month). Animals can receive the last antigen "boost" within one week after being sacrificed. It is often necessary to use an immune adjuvant during the immunization process. Suitable immune adjuvants include Freund's complete adjuvant, Freund's incomplete adjuvant, alum, Ribi adjuvant, Hunter's titer max, saponin adjuvants such as QS21 or Quil A, or immunostimulatory oligonucleotides containing CpG. Other suitable adjuvants are well known in the art. Animals can be immunized subcutaneously, intraperitoneally, intramuscularly, intravenously, intranasally, or by other routes. Specific animals can be immunized with various forms of antigens by various routes. In short, the recombinant antigen of interest can be provided by expressing it with a recombinant cell line. The antigen of interest can be provided in the form of human cells expressing the antigen of interest on its surface. The recombinant form of the antigen of interest can be provided using any previously described method. After the immunization scheme, lymphocytes are isolated from the spleen, lymph nodes or other organs of the animal, and are fused with suitable myeloma cell lines using reagents such as polyethylene glycol to form hybridomas. As described in (Coding, Monoclonal Antibodies: Principles and Practice: Production and Application of Monoclonal Antibodies in Cell Biology, Biochemistry and Immunology, 3rd edition, Academic Press, New York, 1996), after fusion, cells are placed in a culture medium that allows hybridoma growth but does not allow fusion partner growth using standard methods. After culturing hybridomas, analyze whether there is a desired specific antibody in the cell supernatant, i.e., an antibody that selectively binds to an antigen. Suitable analytical techniques include ELISA, flow cytometry, immunoprecipitation and protein blotting. Other screening techniques are well known in the art. Preferred techniques are those that confirm that the antibody binds to the antigen in its intact, natively folded form, such as non-denaturing ELISA, flow cytometry, and immunoprecipitation.

[0249] Importantly, as is well known in the art, only a small portion of an antibody molecule, the antigenic determinant, is involved in the binding of an antibody to its antigenic determinant (see generally Clark, WR (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). For example, the Fc' and Fc regions are effectors of the complement cascade, but do not participate in antigen binding. An antibody whose pFc' region has been enzymatically cleaved, or an antibody without a pFc' region, is called an F(ab')2 fragment, which retains two antigen binding sites of the intact antibody. Similarly, an antibody whose Fc region has been enzymatically cleaved, or an antibody produced without an Fc region, is called a Fab fragment, which retains one antigen binding site of the intact antibody molecule. In other words, the Fab fragment consists of a covalently bound antibody light chain and a portion of an antibody heavy chain, called Fd. The Fd fragment is the major determinant of antibody specificity (a single Fd fragment can associate with up to 10 different light chains without altering antibody specificity), and the Fd fragment retains epitope binding ability when isolated.

[0250] Therefore, in some embodiments, the antibody or antigen-binding fragment thereof in the methods described in the present disclosure refers to F(ab')2, Fab, Fv and Fd fragments. Antibodies can indeed be fragmented using conventional techniques. For example, F(ab')2 fragments can be generated by treating antibodies with pepsin. The resulting F(ab')2 fragments can be treated to reduce disulfide bonds, thereby producing Fab' fragments. Papain digestion can result in the formation of Fab fragments. Fab, Fab' and F(ab')2, scFv, Fv, dsFv, Fd, dAbs, TandAbs, ds-scFv, dimers, small antibodies, double antibodies, bispecific antibody fragments and other fragments can also be synthesized by recombinant technology or chemical synthesis. The technology for producing antibody fragments is well known and described in the art. For example, Beckman et al., 2006; Holliger & Hudson, 2005; Le Gall et al., 2004; Reff & Heard, 2001; Reiter et al., 1996; and Young et al., 1995 each also describe and enable the generation of effective antibody fragments. The various antibody molecules and fragments can be derived from any of the well-known immunoglobulin classes, including but not limited to IgA, secretory IgA, IgE, IgG, and IgM. IgG subclasses are also well known to those skilled in the art, including but not limited to human IgG1, IgG2, IgG3, and IgG4.

[0251] The antibodies or antigen-binding fragments thereof described in the present disclosure also include so-called single-chain antibodies. The term "single domain antibody" (sdAb) or "VHH" refers to a single heavy chain variable domain of an antibody type found in camelid mammals that naturally lack light chains. Such VHHs are also called According to the present invention, the sdAb may in particular be a llama sdAb.

[0252] In some embodiments, the antibody is an antibody or antigen-binding fragment thereof that targets one or more AAV capsid protein(s) or fragments thereof. In some embodiments, the antibody or antigen-binding fragment thereof is a neutralizing antibody or fragment thereof.

[0253] The antibodies or antigen-binding fragments thereof described in the present disclosure can target a protein target, a carbohydrate target, or a glycosylated protein. For example, the antibodies can target the glycosylation groups of the AAV capsid protein.

[0254] In some embodiments, DNA-encoded antibody binders are also referred to as conjugated antibodies or "DNAb"

[0255] The present disclosure also relates to antibodies conjugated to at least one nucleic acid molecule (e.g., DNA barcode) and their use in characterizing the 3D molecular surface features of AAV capsids. Specifically, the present disclosure relates to antibodies (named DNAbs) that utilize DNA barcodes to detect the 3D molecular surface features of AAV capsid variants in a sample. The claimed method is based at least in part on the recognition ability of antibodies and relies on the general idea that each of the antibodies can be associated with a different oligonucleotide DNA barcode, thereby allowing the revelation and quantification of multiple AAV capsids in a sample.

[0256] Thus, in one aspect, the present disclosure relates to a method for binding a linker (e.g., at least one nucleic acid molecule comprising an enzyme cleavable sequence (CL)) and a DNA barcode sequence N1N2N3N4N n The conjugated antibody, wherein N represents a nucleotide and N is an integer greater than 4.

[0257] In one embodiment, the antibody or antibody combination is able to distinguish between active and inactive forms of AAV particles. Thus, the use of such antibodies may be particularly relevant to determining whether the AAV variant is activated. Thus, DNAb can be used as a sensor and can be used to screen AAV variants for infectivity.

[0258] Characterization of the 3D molecular surface features of AAV capsids using phage display libraries

[0259] Phage display libraries expressing transgenic peptides on the surface of phage were originally developed to map epitope binding sites of immunoglobulins. Such libraries can be generated by inserting random oligonucleotides into cDNAs encoding phage surface proteins, thereby generating a collection of phage particles displaying unique peptides with an array.

[0260] In addition to identifying single targeting peptides that are selective for organs, tissues, or cell types, this system has also been used to identify endothelial cell surface markers expressed in mice. In the mouse model system, attachment of therapeutic agents to targeting peptides results in selective delivery of therapeutic agents to the desired organ, tissue, or cell type. Targeted delivery of chemotherapeutic drugs and pro-apoptotic peptides to receptors located in the tumor angiogenic vasculature resulted in a significant increase in therapeutic efficacy and reduction in systemic toxicity in tumor-bearing mouse models.

[0261] Previous in vivo methods for phage display screening resulted in a relatively high background of non-specific phage binding. This is especially true for tissues belonging to the reticuloendothelial system. There is a need for improved phage display methods to reduce non-specific phage binding while retaining specific interactions between targeting peptides and cell receptors. It is also necessary to target receptors of specific cell populations in organs, tissues or cell types. In many cases, tissues or organs can contain highly heterogeneous populations of different cell types. It is necessary to be able to target phage display screening to specific cell populations.

[0262] Identifying previously unknown receptors and previously uncharacterized ligands is a very slow and laborious process. Such new receptors and ligands could provide the basis for new approaches to affinity-based surface mapping using phage display.

[0263] Thus, in one aspect, the present disclosure provides a library of viral particles comprising a plurality of viral particles displaying a plurality of different fusion proteins on their surface, wherein each fusion protein comprises a Protein III or Protein VIII filamentous phage coat protein and at least a portion of a heterologous polypeptide, wherein the heterologous polypeptide is fused to the carboxyl terminus of the filamentous phage coat protein.

[0264] The claimed libraries and methods solve the long-standing needs in the art by providing compositions and methods for identifying and using targeting peptides that are selective for the 3D surface of AAV capsid variants. In some embodiments, the method relates to biological screening and rapid analysis of selective interacting ligands (BRASIL), a new method for phage display that causes background reduction of nonspecific phage binding while retaining selective binding of phage to the 3D surface of AAV capsid variants. In some embodiments, the targeting peptide is identified by exposing a subject to a phage display library, collecting samples of one or more AAV capsid variant libraries, separating the samples into separated AAV particles and phages suspended in an aqueous phase, layering the aqueous phase on an organic phase, centrifuging the two phases so that the AAV-phage complex is precipitated at the bottom of a centrifuge tube, and collecting the AAV-phage complex from the precipitate. In some embodiments, the organic phase is dibutyl phthalate.

[0265] In some embodiments, phages that bind to a specific AAV capsid variant can be pre-screened or post-screened against purified specific AAV capsid variants (which can be nearly 100% pure). Phages that bind to purified specific AAV capsid variants can be sequenced and used as a combined DNA marker to identify the specific AAV capsid variant.

[0266] In some embodiments, after mixing and incubation, targeted phage can be recovered from one or more AAV capsid variant libraries using droplet and / or single cell sequencing technologies. Droplet and / or single cell sequencing technologies allow for large-scale sequencing of individual AAV-phage complexes with very high sequencing accuracy.

[0267] In some embodiments, a phage display library is prepared that displays antigen-binding portions of the 3D surfaces of AAV capsid variants from the library, the library is screened against one or more 3D surfaces of the AAV capsid variants, and phage that binds the antigen is collected. In a more preferred embodiment, the antigen is a 3D peptide combination from the 3D surface of the AAV capsid variant.

[0268] In some embodiments, the methods and compositions can be used to identify one or more 3D surface antigens of the 3D surface of an AAV capsid variant. In some embodiments, the compositions and methods can be used to identify naturally occurring 3D surface antigens of the 3D surface of a known or newly identified AAV capsid variant.

[0269] In some embodiments, the method can include contacting a portion of an AAV capsid that is part of a library of AAV capsid variants. In alternative embodiments, the targeting peptide can comprise a random amino acid sequence.

[0270] Technicians should recognize that the contacting step can utilize complete and complete AAV capsid variants, or can selectively utilize partially complete AAV capsid variants. In some embodiments, the AAV particles to be contacted can be genetically engineered to express recombinant peptides of the targeting peptide. In some embodiments, the targeting peptide is modified with a reactive portion, which allows it to be covalently attached to the 3D surface of the AAV capsid variant. In some embodiments, the reactive portion is a photoreactive group, which, when activated by light, covalently attaches to the receptor. In some embodiments, the peptide is attached to a solid support, and the receptor is purified by affinity chromatography. In some embodiments, the solid support includes magnetic beads, agarose beads, agarose beads, nitrocellulose membranes, nylon membranes, column chromatography matrices, high performance liquid chromatography (HPLC) matrices, or fast high performance liquid chromatography (HPLC) matrices. Those skilled in the art will recognize that the activity of the AAV capsid variant can be determined by a variety of methods known in the art, including but not limited to catalytic activity, binding activity, and TCID50 assays.

[0271] In some embodiments, one or more AAV capsid variants of interest can be identified by the disclosed methods and compositions. One or more targeting peptides that mimic part or all of the naturally occurring 3D surface of an AAV capsid variant can be identified by phage display and in vivo or in vitro biopanning.

[0272] In some embodiments, the 3D molecular surface features of the AAV capsid dictate the tropism and / or neutralization properties of the AAV (e.g., the ability to evade neutralizing antibodies).

[0273] Methods for enriching libraries for characterizing 3D molecular surface features of AAV capsids

[0274] The present disclosure also provides a method for enriching a binding library for characterizing the 3D molecular surface characteristics of AAV capsids, comprising: (a) contacting a pool of binding agents with a first population of AAV capsids; (b) enriching a sub-pool of binding agents that bind to the first population of AAV capsids, thereby enriching the binding library for characterizing the 3D molecular surface characteristics of AAV capsids.

[0275] In some embodiments, the method further comprises: (c) contacting a sub-pool of binders that bind to the first population of AAV capsids with a second population of AAV capsids; and (d) depleting the second sub-pool of aptamers that display affinity for the second population of AAV capsids, thereby selecting a group of binders that have preferential affinity for the population of AAV capsids.

[0276] In some embodiments, positive and negative selections are repeated about or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 times, or more.

[0277] The pool of binding agents described in the present disclosure may include any suitable number of binding agents. In some embodiments, the pool of binding agents includes at least 10, 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 Types, at least 10 20 One or more binding agents.

[0278] The subpools of binding agents described in the present disclosure may include any suitable number of binding agents. In some embodiments, the subpools of binding agents include at least 10, 102 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 Types, at least 10 20 One or more binding agents.

[0279] The first and / or second populations of AAV capsids described herein may include any suitable number of AAV capsids. In some embodiments, the first and / or second populations of AAV capsids include at least 10, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 2 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 10 10 10 11 10 12 10 13 10 14 10 15 10 16 10 17 10 18 10 19 , at least 10 20 or more AAV capsids.

[0280] Any suitable binding library described in this disclosure or known in the art can be enriched using the methods described in this disclosure.In some embodiments, the library of binding agents is an aptamer library, a DNA-encoded chemical library (DECL), a phage display library, or a DNA-encoded antibody library (DEAL).

[0281] In some embodiments, the population of the first and / or second AAV capsids includes one or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVhu.37, AAVrh.8, AAVrh.10, AAVrh.39, AAV11, AAV12, and AAV13, or a combination thereof. In some embodiments, the population of the first and / or second AAV capsids includes other variants derived from mutations, peptide insertions, or shuffling.

[0282] In some embodiments, the 3D molecular surface feature is the binding property of the library. In some embodiments, the binding property is the number, sequence, and copy number of bound binding agents.

[0283] In some embodiments, the 3D molecular surface features of the AAV capsid dictate tropism properties and / or neutralization properties (e.g., the ability to evade neutralizing antibodies).

[0284] The present disclosure also provides a kit comprising an enriched binding library described in the present disclosure. The present disclosure also provides a kit for enriching the binding library described in the present disclosure. The present disclosure also provides a kit for characterizing the 3D molecular surface features of the AAV capsid described in the present disclosure. In some embodiments, the kit includes one or more buffers, primers, probes, fluorophores, quenchers, aptamers, DNA-encoded chemical binders, DNA-encoded antibody binders, and AAV samples. In some embodiments, the kit also includes a manual for implementing the method described in the present disclosure.

[0285] Example

[0286] The present invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

[0287] Example 1: Mapping the 3D features of the AAV capsid using an aptamer library

[0288] Materials and methods

[0289] The following materials and methods were used in the following examples.

[0290] DPBS buffer (1.47 mM KH2PO4, 8 mM Na2HPO4, 138 mM NaCl, 2.67 mM KCl, 0.5 mM MgCl2, 0.9 mM CaCl2, pH 7.4) was used for aptamer library screening. The screening was performed at room temperature.

[0291] Representative aptamers in the linear aptamer library are Figure 1A Representative aptamers in the circular aptamer library are shown in Figure 1Bshown.

[0292] The enrichment of the aptamer library was performed by the following steps:

[0293] Week 1: The circular aptamer library was enriched against AAV Mix 01. Three rounds of enrichment were performed to obtain Pool-1, Pool-2, and Pool-3, respectively.

[0294] Round 1:

[0295] a) Dissolve 5 OD library in 450 μL DPBS buffer. Perform renaturation in a PCR machine;

[0296] b) filtering the renatured library through the Amicon (100 kDa) system;

[0297] c) The filtered liquid was transferred to a 2 mL Eppendorf tube, and 50 μL of AAV mixture (the ratio of aptamer to viral particles was ≥ 10:1) was added, and incubated in a shaker at room temperature for 1 hour;

[0298] d) After incubation, the mixture is filtered through an Amicon system;

[0299] e) washing the AAV-aptamer complex three times with 450 μL DPBS buffer (wash 1, wash 2, wash 3);

[0300] f) resuspend the AAV-aptamer complex with 200 μL DPBS and collect in a 1.5 mL centrifuge tube;

[0301] g) heating in a boiling water bath for 10 minutes (elution);

[0302] h) amplifying the eluted product by electric field driven polymerase chain reaction (ePCR) for 8-12 cycles, and obtaining single-stranded library pool-1 by SDS-PAGE electrophoresis and dialysis;

[0303] i) The concentration of pool-1 was determined at OD260.

[0304] The steps of the second and third rounds of enrichment were the same as the first round, using 0.1 OD of aptamer in each round. The resulting pools-2 and -3 were sequenced. Screening and enrichment of the aptamer library were as follows Figure 2A shown.

[0305] Week 2: The circular aptamer library was enriched against AAV Mix 02. Three rounds of enrichment were performed to obtain Pool-4, Pool-5, and Pool-6, respectively. The steps of the first, second, and third rounds of enrichment were the same as those of the first week. Figure 2B shown.

[0306] Week 3: The linear aptamer library was enriched against AAV Mix 01. Three rounds of enrichment were performed to obtain pools 7, 8, and 9. The steps of the first, second, and third rounds of enrichment were the same as those of the first week.

[0307] Week 4: The linear aptamer library was enriched against AAV Mix 02. Three rounds of enrichment were performed to obtain pools 10, 11, and 12. The steps of the first, second, and third rounds of enrichment were the same as those of the first week.

[0308] The samples in AAV Mix 01 and AAV Mix 02 are shown in Table 1.

[0309] Table 1. Samples in AAV Mix 01 and AAV Mix 02

[0310] Sample ID Virus 1 Virus 2 Virus 3 Virus 4 Virus 5 Virus 6 AAV Mix 01 AAV1 -- -- -- -- -- AAV Mix 02 -- AAV2 AAV3 AAV4 AAV5 AAV6 Sample ID Virus 7 Virus 8 Virus 9 Virus 10 Virus 11 Virus 12 AAV Mix 01 -- -- AAV9 AAV-rh10 AAV-PHP.eB -- AAV Mix 02 AAV7 AAV8 -- -- -- AAV2.7m8

[0311] Details of the screening and enrichment of the libraries are also shown in Table 2.

[0312] Table 2. Screening and enrichment of aptamer libraries

[0313]

[0314]

[0315] Table 3. Enriched aptamer library

[0316]

[0317] Below are the DNA primer sequences used for sequencing each enrichment pool. For example, LibP1S021 is the forward sequencing primer for the sample labeled as pool 01-1 (see Table 3 above); LibP1S025 is the primer sequence for the blank control sample.

[0318] LibP1 samples

[0319] LibP1S021 ATATCATTCAGCACTCCACGCATAGC Pool 1 sequence primer

[0320] LibP1S022 ATCTCCTTCAGCACTCCACGCATAGC Pool 2 sequence primer

[0321] LibP1S023 ATGTCGTTCAGCACTCCACGCATAGC Pool 4 sequence primer

[0322] LibP1S024 ATTTCTTTCAGCACTCCACGCATAGC Pool 5 sequence primer

[0323] LibP1S025 CAATGATTCAGCACTCCACGCATAGC Mix1 sequence primer

[0324] LibTOR Sample

[0325] LibTORS021 ATATCACCTCTCTATGGGCAGTCGGTGAT Pool 7 sequence primers

[0326] LibTORS022 ATCTCCCCTCTCTATGGGCAGTCGGTGAT Pool 8 sequence primers

[0327] LibTORS023 ATGTCGCCTCTCTATGGGCAGTCGGTGAT Pool 10 sequence primers

[0328] LibTORS024 ATTTCTCCTCTCTATGGGCAGTCGGTGAT Pool 11 sequence primer

[0329] LibTORS025 CAATGACCTCTCTATGGGCAGTCGGTGATMix2 sequence primer

[0330] Enrichment of the same aptamer library against two different AAV samples

[0331] Figure 6 The enrichment results of the same circular aptamer library for two different AAV samples (AAV Mix 01 and AAV Mix 02) are shown, as well as the distribution of common aptamer sequences between the enriched libraries of the two samples. The results of two rounds of enrichment are shown, and the enrichment was repeated in two parallel experiments.

[0332] Specifically, in the first parallel experiment, in any round of enrichment, 161 enriched aptamers had counts greater than 50. In the second parallel experiment, in any round of enrichment, 172 enriched aptamers had counts greater than 50. These results show good reproducibility of enrichment of the aptamer library.

[0333] For the enrichment of the circular aptamer library against AAV Mix 01, 80 aptamers were enriched after the second round of enrichment in the first parallel experiment, and 86 aptamers were enriched after the second round of enrichment in the second parallel experiment, indicating good reproducibility of the enrichment.

[0334] For the enrichment of the circular aptamer library against AAV Mix 02, 69 aptamers were enriched after the second round of enrichment in the first parallel experiment, and 73 aptamers were enriched after the second round of enrichment in the second parallel experiment, indicating good reproducibility of the enrichment.

[0335] The same linear aptamer library was enriched for two different AAV samples (AAV Mix 01 and AAV Mix 02), and the distribution of common aptamer sequences between the enriched libraries of these two samples was analyzed again. Results of two rounds of enrichment are shown, and the enrichment was repeated in two parallel experiments.

[0336] Specifically, in the first parallel experiment, in any round of enrichment, 49 enriched aptamers had counts greater than 50. In the second parallel experiment, in any round of enrichment, 49 enriched aptamers had counts greater than 50. These results show good reproducibility of enrichment of the aptamer library.

[0337] For the enrichment of the linear aptamer library against AAV Mix 01, 45 aptamers were enriched after the second round of enrichment in the first parallel experiment, and 41 aptamers were enriched after the second round of enrichment in the second parallel experiment, indicating good reproducibility of the enrichment.

[0338] For the enrichment of the linear aptamer library against AAV Mix 02, 45 aptamers were enriched after the second round of enrichment in the first parallel experiment, and 40 aptamers were enriched after the second round of enrichment in the second parallel experiment, indicating good reproducibility of the enrichment.

[0339] In conclusion, the number of shared aptamer sequences between the enriched aptamer libraries for two different AAV samples remained relatively constant in multiple parallel experiments, indicating that the enrichment of AAV sample-specific aptamer libraries was reproducible and efficient.

[0340] Next, the counts of shared aptamer sequences between the enriched aptamer libraries were analyzed for two different AAV samples to determine their ability to distinguish between the two AAV samples.

[0341] like Figure 7A-7B As shown in Figure 2, the counts of shared circular aptamer sequences in each enriched aptamer library were significantly different (the p-values ​​for the first and second rounds were 9.9 × 10 -12 and 3.8×10 -12 ).

[0342] like Figure 7C-7D As shown, the counts of shared linear aptamer sequences in each enriched aptamer library were significantly different (p-values ​​were 0.02 and 0.01 for the first and second rounds, respectively).

[0343] Data quality analysis

[0344] The quality of the enriched aptamer library was evaluated and the results are shown in Table 4. Specifically, the percentage of aptamer sequences with lengths outside the range of 36-45 bp was calculated.

[0345] Table 4. Quality of the enriched aptamer library

[0346] First round Round 2 Circular Library 0.039 0.06 Linear library 0.048 0.091

[0347] For the enriched aptamers, the counts and the distribution of the number of sequences corresponding to the counts were mapped for each enriched circular and linear library. Figures 8A-8B The distribution of the enriched circular libraries from the first and second rounds of enrichment are shown, respectively. Figures 9A-9B The distribution of the enriched linear libraries for the first and second rounds of enrichment are shown, respectively. Based on these data, a cutoff value of 50 counts for the enriched aptamers for additional analysis was reasonable.

[0348] Example 2: 3D Mapping of AAV Capsids Using DNA Encoded Libraries (DELs) Materials and Methods

[0349] The following materials and methods were used in the following examples. Figure 10-13 A schematic representation of the enrichment of the DECL library described in the present disclosure is shown.

[0350] DPBS buffer (1.47 mM KH2PO4, 8 mM Na2HPO4, 138 mM NaCl, 2.67 mM KCl, 0.5 mM MgCl2, 0.9 mM CaCl2, pH 7.4) was used for aptamer library screening and enrichment against AAV targets. Screening was performed at room temperature.

[0351] Specifically, one tube of DEL library (3.23 nmol / tube) was centrifuged at 12000 rpm for 10 minutes and dissolved in 150 μL DPBS. The dissolved DEL library was dissolved at 4°C overnight.

[0352] Four AAV samples were used for enrichment: wild-type AAV2, AAV2 mutant AAV2.7m8 with a single point mutation, wild-type AAV9, and AAV9 mutant AAV-PHP.eB with a single point mutation. Two tubes (50 μL each) were used for each sample, and 100 μL was obtained for each sample.

[0353] 13 centrifuge tubes (2 mL each) were labeled as tubes 1-13. 460 μL DPBS and 10 μL DEL library were added to each tube. 30 μL of AAV sample was added to each tube as shown in Table 5.

[0354] Table 5. AAV samples used to enrich DEL libraries

[0355]

[0356] 500 μL of liquid from each independent group was added to a 100 kDa Amicon Ultra-0.5 system and filtered, centrifuged at 14000 g for 5 minutes. After centrifugation, 450 μL of DPBS was added to each tube and gently mixed. The mixture was incubated for 30 minutes and then centrifuged at 14000 g for 5 minutes. This washing step was repeated twice, so that each sample was washed three times in total.

[0357] After the washing step, about 30 μL of the AAV-DEL mixture in each ultracentrifuge tube was collected for PCR amplification. The forward primer (primer F) (4 nmol / tube) and the reverse primer (primer R) (4 nmol / tube) were taken out from the kit, centrifuged at 12000 rpm for 10 minutes, and added to 400 μL ddH2O to dissolve. 10 μM of each primer was obtained.

[0358] The AAV-DEL mixture obtained in the above steps was used as a template for PCR amplification. The PCR reaction is shown in Table 6.

[0359] Table 6. PCR amplification of AAV-DEL mixture

[0360]

[0361]

[0362] The PCR amplification conditions are shown in Table 7.

[0363] Table 7. PCR amplification conditions

[0364]

[0365] The PCR products were purified using the QIAGEN-MinElute kit (QIAGEN, 28006). 10 liters of purified product were obtained from each reaction. These tubes were labeled as independent groups 1-13.

[0366] The packing list of DEL kit is as follows Fig.14 The protocol for the QIAGEN-MinElute kit is as follows:

[0367] MinElute PCR Purification Kits (cot. nos. 28004 and 28006) can be stored at room temperature (15-25°C) for up to 12 months unless otherwise stated on the label. Upon arrival, store the spin columns at 2-8°C.

[0368] Notes before you begin:

[0369] This protocol is suitable for purification of up to 5 μg of PCR product (70 bp to 4 kb).

[0370] • Before use, add ethanol (96-100%) to buffer the PE concentrate (see bottle label for volume).

[0371] • All centrifugation steps were performed at room temperature (15-25°C) at 17,900 x g (13,000 rpm) in a conventional benchtop microcentrifuge.

[0372] Add 1:250 volume of pH indicator I to buffer PB. Add pH indicator I to the entire buffer content. Do not add pH indicator I to buffer aliquots. The yellow color of buffer PB with pH indicator I indicates pH values ​​of 5,7.5. Adsorption of DNA to the membrane is effective only at pH values ​​of 5,7.5.

[0373] Note: If the purified PCR product is to be used for sensitive microarray applications, using Buffer PB without the addition of pH Indicator I can be beneficial.

[0374] Table 8 below shows the quality check of PCR products before and after purification.

[0375] Table 8. PCR product quality before and after purification

[0376]

[0377] DEL library enriched for AAV samples.

[0378] In this experiment, four groups of AAV samples were used: wild-type AAV2, AAV2 mutant AAV2.7m8 with a single point mutation, wild-type AAV9, and AAV9 mutant AAV-PHP.eB with a single point mutation. Three parallel experiments were performed for each group of AAV samples, and one control sample was included.

[0379] The 13 groups of samples were compared with 10 14 The same DEL library of 100 candidates was incubated together. The combined candidates in each group were sequenced, and the results are shown in Table 9.

[0380] Table 9. Binding of DELs to AAV samples

[0381] sample Enrichment in 1 sample Enriched in 2 samples Enriched in 3 samples DL 2-4 21379 131 8 DL 5-7 13699 609 88 DL 8-10 25039 209 9 DL 11-13 12694 191 14

[0382] In Table 9, the "Enriched in 1 sample" column shows the number of DEL barcodes obtained from 1 of the 3 samples, the "Enriched in 2 samples" column shows the number of DEL barcodes obtained from 2 of the 3 samples, and the "Enriched in 3 samples" column shows the number of DEL barcodes obtained from all 3 samples.

[0383] Fig.15 The Venn diagram of the DEL barcodes sequenced in each group is shown. The 1056 overlapping sequences obtained from 2 or 3 samples in each group were further analyzed in cluster analysis. Figures 16A-16D As shown. Cluster analysis was performed using principal component analysis (PCA). The enriched DEL barcode sequences were projected into 5 dimensions, and in the first experiment, in which overlapping sequences obtained from 2 or 3 samples in each group were analyzed, 31% of the data on the first axis fell in the first principal component (PC), 12% fell in the second principal component, 10% fell in the third principal component, 8% fell in the fourth principal component, and 7% fell in the 5% principal component. The explained variance ratio of the first five principal components (PC) was [0.31003056 0.121422140.102502430.08667515 0.07822148]. In the second experiment, overlapping sequences obtained from 2 samples in each group were analyzed, and 36% of the data on the first axis fell in the first principal component (PC), 13% fell in the second principal component, 10% fell in the third principal component, 8% fell in the fourth principal component, and 5% fell in the 5% principal component. The explained variance ratio of the first five principal components (PCs) is [0.36153258 0.13173036 0.10887119 0.08723116 0.05947605].

[0384] Other Implementations

[0385] It should be understood that although the invention has been described in conjunction with its detailed description, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.

[0386] Additional embodiments

[0387] Embodiment A1. A virus particle library comprising a plurality of virus particles displaying a plurality of different fusion proteins on their surface, wherein each fusion protein comprises at least a portion of a protein III or protein VIII filamentous phage coat protein and a heterologous polypeptide, wherein the heterologous polypeptide is fused to the carboxyl terminus of the filamentous phage coat protein.

[0388] Embodiment A2. The library according to embodiment A1, wherein the fusion protein comprises a full-length bacteriophage coat protein.

[0389] Embodiment A3. The library according to embodiment A1, wherein the bacteriophage coat protein is a wild-type protein.

[0390] Embodiment A4. The library according to embodiment A1, wherein the heterologous polypeptide comprises about 4 to about 80 amino acid residues.

[0391] Embodiment A5. The library according to embodiment A1, wherein the heterologous polypeptide comprises at least about 100 amino acid residues.

[0392] Embodiment A6. The library according to embodiment A1, wherein the heterologous polypeptide is attached to the coat protein via a linker peptide.

[0393] Embodiment A7. The library according to embodiment A6, wherein the linker peptide has about 4 to about 30 residues.

[0394] Embodiment A8. The library according to embodiment A7, wherein the linker peptide has about 8 to about 20 residues.

[0395] Embodiment A9. The library according to embodiment A6, wherein more than about 50% of the residues in the linker peptide are glycine or serine.

[0396] Embodiment A10. The library according to embodiment A1, wherein the filamentous phage is selected from the group consisting of M13, fl and fd filamentous phage.

[0397] Embodiment A11. A composition comprising a modified AAV capsid protein, wherein the capsid protein comprises AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and other variants derived from mutation, peptide insertion, or shuffling:

[0398] Embodiment A12. A pharmaceutical preparation comprising the composition of Embodiment A11, further comprising one or more pharmaceutically acceptable carriers, buffers, diluents or excipients.

[0399] Embodiment A13. A nucleic acid vector comprising a nucleic acid segment encoding a modified AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and other variants derived from mutation, peptide insertion, or shuffling.

[0400] Embodiment A14. The nucleic acid vector according to embodiment A13, wherein the nucleic acid segment is integrated into a host cell.

[0401] Embodiment A15. The nucleic acid vector according to embodiment A14, wherein the host cell is a mammalian cell.

[0402] Embodiment A16. A pharmaceutical preparation comprising the host cell of embodiment A14, further comprising one or more pharmaceutically acceptable carriers, buffers, diluents or excipients.

[0403] Embodiment A17. A method for enriching barcode constructs from a sequence library generated from a plurality of AAV particles or bacteriophage viruses, comprising capturing DNA library molecules from the library by targeting one or more AAV particles to identify barcodes and / or target transcripts.

[0404] Embodiment A18. A method according to embodiment A17, wherein the method is a method of mixing an AAV variant library of any size (from a library comprising one type of AAV variant to a library comprising many different types of AAV variants) with a phage display library, which can be any phage display library used for affinity screening.

[0405] Embodiment A19. A method according to embodiment A18, wherein the method is a method for identifying AAV particle genomes from at least one phage virus or phage virus subpopulation, the method comprising enriching library molecules from at least one phage virus or phage virus subpopulation based on one or more unique AAV particle identification barcodes, wherein the targeted barcode identifies transcripts of individual phages represented in the sequencing library.

[0406] Embodiment A20. A method according to any one of Embodiments A17-A19, comprising:

[0407] a) simultaneously capturing AAV particle genome sequences and phage DNA library molecules from a mixture of an AAV library and a phage display library by single droplet sequencing technology and / or modified single cell sequencing technology;

[0408] b) sequencing the captured DNA library molecules, wherein the captured DNA library molecules comprise AAV capsid genome sequences and phage genome sequences;

[0409] c) identifying the AAV particle identification barcode associated with the captured phage DNA library molecule; and

[0410] d) capturing phage DNA library molecules from the phage display library by targeting the identified AAV particle identification barcode,

[0411] Phage DNA constructs associated with individual AAV variants were thereby enriched.

[0412] Embodiment A21. A method according to any one of embodiments A17-A20, wherein capturing comprises PCR amplifying one or more AAV particles and phage DNA library molecules using a primer pair complementary to each of the one or more AAV particles and phage DNA library molecules, wherein the primer pair comprises a primer comprising a complementary sequence to all or part of the AAV particle and phage identification barcode or a complementary sequence to the target transcribed sequence of each of the one or more AAV particles and phage DNA library molecules.

[0413] Embodiment A22. The method according to any one of Embodiments A17 to A21, wherein the capture comprises PCR amplification of one or more AAV particles and phage DNA library molecules specific for at least one individual or subpopulation of the AAV variant library and the phage display library.

[0414] Embodiment A23. A method according to embodiment A22, wherein PCR amplification comprises contacting the library with a 5' primer and a 3' primer, wherein the 5' primer or the 3' primer comprises a nucleotide sequence complementary to a unique barcode of a single viral genome from an AAV variant library and a phage display library; and amplifying library molecules comprising a unique barcode of a single AAV particle and phage DNA; thereby obtaining multiple transcripts from a single AAV particle and phage DNA.

[0415] Embodiment A24. The method according to Embodiment A23, wherein:

[0416] a) the 5' primer comprises a nucleotide sequence complementary to a 5' universal primer site contained in each library molecule and a nucleotide sequence complementary to a unique barcode, and the 3' primer comprises a nucleotide sequence complementary to a 3' universal primer site contained in each library molecule;

[0417] b) the 5' primer comprises a nucleotide sequence complementary to a 5' universal primer site contained in each library molecule, and the 3' primer comprises a nucleotide sequence complementary to a 3' universal primer site contained in each library molecule and a nucleotide sequence complementary to a unique barcode;

[0418] c) the 5' primer comprises a nucleotide sequence complementary to a 5' universal primer site different from the 5' universal primer site contained in each library molecule and a nucleotide sequence complementary to the unique barcode, and the 3' primer comprises a nucleotide sequence complementary to the 3' universal primer site contained in each library molecule; or

[0419] d) the 5' primer includes a nucleotide sequence complementary to a 5' universal primer site contained in each library molecule, and the 3' primer includes a nucleotide sequence complementary to a 3' universal primer site different from the 3' universal primer site contained in each library molecule and a nucleotide sequence complementary to a unique barcode.

[0420] Embodiment A25. A method according to any one of embodiments A1-A24, wherein single or combinations of AAV variant capsids can be identified by a combinatorial index of any combination of phage displayed DNA and / or peptide sequences, the combinatorial index representing different binding affinities between any AAV variant particle and its corresponding phage virus, which may vary in binding affinity.

[0421] Embodiment A26. A method according to embodiment A25, wherein this combined index of phage displayed DNA and / or peptide sequences of any given AAV variant particle is used as training data and test data for computational prediction of other AAV capsid tropisms using various deep learning algorithms.

[0422] Embodiment A27. An antibody conjugated to at least one nucleic acid molecule, the at least one nucleic acid molecule comprising an enzyme cleavable sequence (CL) and a DNA barcode sequence N1N2N3N4N n , wherein N represents a nucleotide, and n represents an integer greater than 4.

[0423] Embodiment A28. An antibody according to embodiment A27, which is selected from the group consisting of: monoclonal antibodies, antibody fragments comprising an antigen binding domain such as Fab', Fab, F(ab')2, single domain antibodies (DAB or VHH), TandAbs dimers, Fv, scFv (single chain Fv), dsFv, ds-scFv, Fd, linear antibodies, mini antibodies, diabodies, bispecific antibody fragments, diabodies, triabodies (scFv-Fab fusion, bispecific or trispecific, respectively); sc-diabodies; kappa (lambda) bodies (scFv-CL fusions); DVD-Ig (dual variable domain antibodies, bispecific formats); SIP (small immune protein, a mini antibody); SMIP ("small modular immunodrug" scFv-Fc dimer; DART (ds-stable diabody "dual targeting"); small antibody mimetics comprising one or more CDRs.

[0424] Embodiment A29. The antibody according to embodiment A28, which may be a monoclonal and / or polyclonal antibody.

[0425] Embodiment A30. The antibody according to embodiment A27, wherein the nucleic acid molecule is bound to an acceptor glutamine residue present in the antibody via a linking agent.

[0426] Embodiment A31. An antibody comprising an acceptor glutamine functionalized with a nucleic acid molecule via a linking agent, the nucleic acid molecule comprising an enzyme cleavable sequence (CL) and a DNA barcode sequence N1N2N3N4N n , wherein N represents a nucleotide, and n represents an integer greater than 4.

[0427] Embodiment A32. The antibody according to any one of embodiments A27-A31, wherein the linker is covalently bound to the side chain of an acceptor glutamine within the primary sequence of the antibody.

[0428] Embodiment A33. The antibody according to any one of embodiments A27-A32, wherein the linker is covalently bound to the side chain of an amino acid within the CH2 domain.

[0429] Embodiment A34. An antibody according to any one of embodiments A27-A33, wherein the acceptor glutamine is within an enzyme recognition tag fused to the C-terminus of the CH3 domain.

[0430] Embodiment A35. The antibody according to embodiments A27-A34, wherein the acceptor glutamine is within an enzyme recognition tag fused to the C-terminus of the CK domain.

[0431] Embodiment A36. The antibody according to embodiment A35, wherein the acceptor glutamine is at the position corresponding to residue Q295 in the primary sequence of CH2 according to Kabat EU numbering.

[0432] Embodiment A37. The antibody according to any one of Embodiments A27-A36, wherein the CH2 domain contains no N-linked glycosylation.

[0433] Embodiment A38. The antibody according to any one of Embodiments A27-A36, wherein the CH2 domain comprises N-linked glycosylation.

[0434] Embodiment A39. An antibody according to any one of the above embodiments, wherein the antibody comprises a functionalized receptor glutamine having formula IVa:

[0435] (Q)-NH-(C)-(CL-(P 1 -ZP 2 )) q Formula IVa

[0436] in:

[0437] -Q is a glutamine residue present in the antibody;

[0438] -C is the bond or connecting part

[0439] -q is an integer selected from 1, 2, 3 or 4;

[0440] -CL is an enzyme-cleavable nucleic acid sequence;

[0441] -P 1 independently absent, or having a nucleic acid of at least 10 nucleotides;

[0442] -Z is the DNA barcode sequence N1N2N3N4N n , wherein N represents a nucleotide, and n represents an integer greater than 4; and

[0443] -P 2 A nucleic acid having at least 10 nucleotides is independently absent or present.

[0444] Embodiment A40. An antibody according to any one of the above embodiments, wherein the antibody comprises a functionalized acceptor glutamine residue having formula IVb,

[0445] (Q)-NH-(C)-((M)) q Formula IVb

[0446] in:

[0447] -Q is a glutamine residue present in the antibody;

[0448] -C is the bond or connecting part

[0449] -q is an integer selected from 1, 2, 3 or 4;

[0450] -M is independently: (RR')-C'-(CL'-(P 1 -ZP 2 ) q' ,

[0451] -in

[0452] -(RR') is the addition product between R and the complementary reactive moiety R';

[0453] -C' is a bond or connecting moiety;

[0454] -CL' is an enzyme-cleavable nucleic acid sequence;

[0455] -P 1 independently absent, or having a nucleic acid of at least 10 nucleotides;

[0456] -Z is the DNA barcode sequence N1N2N3N4N n , wherein N represents a nucleotide, and n represents an integer greater than 4;

[0457] -P 2 independently lacking or having a nucleic acid of at least 10 nucleotides; and

[0458] -q' is an integer selected from 1, 2, 3 or 4.

[0459] Embodiment A41. A linking agent or antibody-conjugated linking agent having the general formula Ia:

[0460] G-NH-C-(CL-(P 1 -ZP 2 )) q Formula Ia

[0461] in:

[0462] -G is H, an amine protecting group, or, when conjugated, an antibody or antibody fragment attached via an amide bond;

[0463] -C is a bond or connecting moiety;

[0464] -q is an integer selected from 1, 2, 3 or 4;

[0465] -CL' is independently absent, or an enzyme-cleavable nucleic acid sequence;

[0466] -P 1 independently absent, or having a nucleic acid of at least 10 nucleotides;

[0467] -Z is the DNA barcode sequence N1N2N3N4N n , wherein N represents a nucleotide, and n represents an integer greater than 4; and

[0468] -P 2 Independently absent, or having a nucleic acid of at least 10 nucleotides.

[0469] Embodiment A42. An antibody or linking agent according to embodiments A39-A41, wherein C is a substituted or unsubstituted alkyl or heteroalkyl chain, optionally wherein any carbon of the chain is substituted by alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C(O)S-, amine, alkylamine, amide or alkylamide.

[0470] Embodiment A43. An antibody or linking agent according to any one of Embodiments A39-A41, wherein C comprises the unit: - (C) n -XL-,

[0471] Among them: (C) nis a substituted or unsubstituted alkyl or heteroalkyl chain, optionally wherein any carbon of the chain is substituted with alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C(O)S-, amine, alkylamine, amide or alkylamide; n is an integer selected from the range of 2 to 20; X is NH, O, S, absent, or a bond; L is independently absent, a bond or a continuation of a bond, or a carbon-containing framework of 5 to 200 atoms substituted at one or more atoms, optionally wherein the carbon-containing framework comprises a linear framework of 5 to 30 carbon atoms optionally substituted at one or more atoms, optionally wherein the carbon-containing framework is a linear hydrocarbon, a symmetrically or asymmetrically branched hydrocarbon, a monosaccharide, a disaccharide, a linear or branched oligosaccharide (asymmetrically branched or symmetrically branched), other naturally occurring linear or branched oligomers (asymmetrically branched or symmetrically branched), or a dimer, trimer or higher oligomer (linear, asymmetrically branched or symmetrically branched) produced by any chain growth or step growth polymerization process.

[0472] Embodiment A44. An antibody according to any one of embodiments A40 or A42-A43, wherein RR' comprises an addition product of a thio-maleimide (or haloacetamide) addition, such as an N,S-disubstituted-3-thio-pyrrolidine-2,5-dione; a Staudinger connection, such as an N,3- or N,4-substituted-5-diphenylphosphine oxide-benzamide; a Huisgen connection 1,3-cycloaddition (click reaction), such as N,S-disubstituted-3-thio-pyrrolidine-2,5-diones, 1,4-disubstituted-1,2,3-triazoles, 3,5-disubstituted-isoxazoles or 3,5-disubstituted-tetrazoles; Diels-Alder cycloaddition adducts, such as 2,4-cycloaddition products between O- or N-substituted-5-norbornene-2-carboxylates or amides, N-substituted-5-norbornene-2,3-dicarboxylic acid imides, O- or N-substituted-7-oxonorbornene-5-carboxylates or amides, or N-substituted-7-oxonorbornene-5,6-dicarboxylic acid imides and 9-substituted anthracenes or 3-substituted 1,2,4,5-tetrazines; or any high yield selective amidation or imidization reaction.

[0473] Embodiment A45. The antibody according to any one of embodiments A40 or A42-A43, wherein RR' comprises the result of reaction of an alkyne with an azide.

[0474] Embodiment A46. The antibody according to embodiment A45, wherein RR' comprises the following structure:

[0475]

[0476] Embodiment A47. A compound having the structure of Formula III,

[0477] R'-L-(CL-(P 1 -ZP 2 )) q Formula III

[0478] in:

[0479] R' is a reactive group;

[0480] L is independently absent or substituted at one or more atoms of a carbon-containing framework of 1 to 200 atoms, optionally wherein the carbon-containing framework comprises a linear framework of 5 to 30 atoms optionally substituted at one or more atoms, optionally wherein the carbon-containing framework is a linear hydrocarbon, a symmetrically or asymmetrically branched hydrocarbon, a monosaccharide, a disaccharide, a linear or branched oligosaccharide (asymmetrically branched or symmetrically branched), other naturally occurring linear or branched oligomers (asymmetrically branched or symmetrically branched), or a dimer, trimer or higher oligomer (linear, asymmetrically branched or symmetrically branched) produced by any chain growth or step growth polymerization process;

[0481] CL is independently absent, or an enzyme-cleavable nucleic acid sequence;

[0482] P 1 independently absent, or having a nucleic acid of at least 10 nucleotides;

[0483] Z is the DNA barcode sequence N1N2N3N4N n , wherein N represents a nucleotide, and n represents an integer greater than 4;

[0484] P 2 independently lacking or having a nucleic acid of at least 10 nucleotides; and

[0485] q is an integer selected from 1, 2, 3 or 4.

[0486] Embodiment A48. An antibody according to any one of the above embodiments, which is specific for an immune cell regulatory molecule, a cancer antigen, a viral antigen, a bacterial antigen or a CD molecule.

[0487] Embodiment A49. The antibody according to any one of the above embodiments, wherein the enzymatically cleavable sequence CL comprises a restriction enzyme cleavage site.

[0488] Embodiment A50. The antibody according to embodiment A49, wherein the enzymatically cleavable sequence is selected from Table B.

[0489] Embodiment A51. An antibody according to any of the above embodiments, wherein the DNA barcode comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 nucleotides.

[0490] Embodiment A52. The antibody according to embodiment A51, wherein sequence P1 comprises 10 to 15 nucleotides.

[0491] Embodiment A53. The antibody according to any one of the above embodiments, wherein the nucleic acid molecule further comprises a sequence P1 of at least 10 nucleotides.

[0492] Embodiment A54. An antibody according to embodiment A50 or A52, wherein the nucleic acid molecule has the general formula: 3'-CL-P1-N1N2N3N4N n -5'.

[0493] Embodiment A55. The antibody according to any one of the above embodiments, wherein the nucleic acid molecule further comprises a second sequence P2 having at least 10 nucleotides.

[0494] Embodiment A56. The antibody according to embodiment A55, wherein sequence P2 comprises 10 to 15 nucleotides.

[0495] Embodiment A57. An antibody according to embodiment A56, wherein the nucleic acid molecule has the general formula: 3'-CL-P1-N1N2N3N4N n -P2-5', where

[0496] -CL indicates an enzyme-cleavable sequence

[0497] -P1 represents the first sequence that can hybridize with the first forward primer

[0498] -N1N2N3N4N n Represents a DNA barcode, where N represents a nucleotide and n is an integer greater than 4

[0499] -P2 represents a second sequence capable of hybridizing with the second reverse primer

[0500] Embodiment A58. An antibody according to any one of the above embodiments, wherein the nucleic acid molecule comprises the sequence:

[0501] GAATTCCCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNATCACCGACTGCCCATAGAGAGG.

[0502] Embodiment A59. A method for conjugating a DNA barcode sequence to an antibody, comprising the steps of:

[0503] a) providing an antibody having at least one acceptor glutamine residue;

[0504] b) reacting the antibody with a linking agent comprising a primary amine and a compound comprising (i) an enzyme cleavable sequence (CL) and a DNA barcode sequence N1N2N3N4N in the presence of TGase under conditions sufficient to obtain an antibody comprising an acceptor glutamine linked to the DNA barcode sequence via the linking agent. n A nucleic acid molecule wherein N represents a nucleotide and n represents an integer greater than 4.

[0505] Embodiment A60. A method for conjugating a DNA barcode sequence to an antibody, comprising the steps of:

[0506] a) providing an antibody having at least one acceptor glutamine residue;

[0507] b) reacting the antibody with a linking agent comprising a primary amine and a reactive group (R) in the presence of TGase under conditions sufficient to obtain an antibody comprising an acceptor glutamine linked (covalently) to a reactive group (R) via the linking agent; and

[0508] c) reacting the antibody obtained in step b) with a compound under conditions sufficient to obtain the antibody, the compound comprising (i) an enzyme cleavable sequence (CL) and a DNA barcode sequence N1N2N3N4N n A nucleic acid molecule, wherein N represents a nucleotide and n represents an integer greater than 4, and (ii) a reactive group (R') capable of reacting with a reactive group R, the antibody comprising an acceptor glutamine linked to the DNA barcode sequence via a linking agent.

[0509] Embodiment A61. A method according to embodiment A59 or A60, wherein the linking reagent of step (a) is covalently bound to the side chain of an acceptor glutamine within the primary sequence of the antibody.

[0510] Embodiment A62. A method according to embodiment A59 or A60, wherein the linking reagent of step (a) is covalently bound to the side chain of an amino acid within the CH2 domain.

[0511] Embodiment A63. A method according to embodiment A59 or A60, wherein the acceptor glutamine is within an enzyme recognition tag fused to the C-terminus of the CH3 domain.

[0512] Embodiment A64. A method according to embodiment A59 or A60, wherein the acceptor glutamine is within an enzyme recognition tag fused to the C-terminus of the CK domain.

[0513] Embodiment A65. A method according to embodiment A64, wherein the acceptor glutamine is at a position in the primary sequence of CH2 corresponding to residue Q295 according to Kabat EU numbering.

[0514] Embodiment A66. The method according to any one of Embodiments A59-A65, wherein the CH2 domain contains no N-linked glycosylation.

[0515] Embodiment A67. The method according to any one of Embodiments A59-A65, wherein the CH2 domain comprises N-linked glycosylation.

[0516] Embodiment A68. A method according to any one of Embodiments A59-A65, wherein the linking reagent comprising a reactive group has the general formula Ib:

[0517] G-NH-(C)-(R)q Formula Ib

[0518] in:

[0519] G is H, an amine protecting group, or, when conjugated, an antibody or antibody fragment attached via an amide bond;

[0520] C is a bond or connecting part;

[0521] q is an integer selected from 1, 2, 3 or 4; and

[0522] R is the reactive moiety.

[0523] Embodiment A69. An antibody or linking agent according to embodiment A58, wherein C comprises the unit: - (C) n -XL-,

[0524] in:

[0525] (C) n is a substituted or unsubstituted alkyl or heteroalkyl chain, optionally wherein any carbon of the chain is substituted with alkoxy, hydroxy, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C(O)S-, amine, alkylamine, amide or alkylamide;

[0526] n is an integer selected from the range of 2 to 20;

[0527] X is NH, O, S, absent, or a bond;

[0528] L is independently absent, or a bond or continuation of bonds, or a carbon-containing framework of 5 to 200 atoms substituted at one or more atoms, optionally wherein the carbon-containing framework comprises a linear framework of 5 to 30 carbon atoms optionally substituted at one or more atoms, optionally wherein the carbon-containing framework is a linear hydrocarbon, a symmetrically or asymmetrically branched hydrocarbon, a monosaccharide, a disaccharide, a linear or branched oligosaccharide (asymmetrically branched or symmetrically branched), other naturally occurring linear or branched oligomers (asymmetrically branched or symmetrically branched), or a dimer, trimer or higher oligomer (linear, asymmetrically branched or symmetrically branched) produced by any chain growth or step growth polymerization process.

[0529] Embodiment A70. The method according to any one of Embodiments A59-A69, wherein the compound comprising a DNA barcode sequence and a reactive group (R') has the general formula III:

[0530] R'-L-(CL-(P 1 -ZP 2 )) q Formula III

[0531] in:

[0532] R' is a reactive group;

[0533] L is independently absent or is a carbon-containing framework of 1 to 200 atoms substituted at one or more atoms, optionally wherein the carbon-containing framework comprises a linear framework of 5 to 30 atoms optionally substituted at one or more atoms, optionally wherein the carbon-containing framework is a linear hydrocarbon, a symmetrically or asymmetrically branched hydrocarbon, a monosaccharide, a disaccharide, a linear or branched oligosaccharide (asymmetrically branched or symmetrically branched), other naturally occurring linear or branched oligomers (asymmetrically branched or symmetrically branched), or a dimer, trimer or higher oligomer (linear, asymmetrically branched or symmetrically branched) produced by any chain growth or step growth polymerization process;

[0534] CL is independently absent, or an enzyme-cleavable nucleic acid sequence;

[0535] P 1 independently absent, or having a nucleic acid of at least 10 nucleotides;

[0536] Z is the DNA barcode sequence N1N2N3N4N n , wherein N represents a nucleotide, and n represents an integer greater than 4;

[0537] P 2 independently lacking or having a nucleic acid of at least 10 nucleotides; and

[0538] q' is an integer selected from 1, 2, 3 or 4.

[0539] Embodiment A71. An antibody obtained according to the method of any one of Embodiments A59-A70.

[0540] Embodiment A72. A method for detecting the presence of at least one antigen (herein the antigen refers to the 3D molecular surface features of AAV capsid variants) in a sample (herein the sample refers to AAV particles in solution or on a solid support), comprising the following steps: providing at least one antibody specific for the antigen of any one of embodiments A27-A58 or A71, contacting the sample with a certain amount of the at least one antibody under conditions that effectively allow binding between the antibody and the antigen, washing the sample to remove unbound antibody, contacting the sample with an enzyme capable of cleaving sequence C1, isolating the released DNA barcodes, and sequencing the DNA barcodes, wherein the presence and number of the barcodes indicate the presence and number of the antigens in the sample.

[0541] Embodiment A73. A method according to embodiment A72, wherein the antigen is carried by DNAb-AAV particles.

[0542] Embodiment A74. The method according to any one of Embodiments A72-A73, wherein the sample consists of a heterogeneous mixture of DNA b-AAV-particles.

[0543] Embodiment A75. A method according to embodiment A74, wherein the heterologous DNAb-AAV-particle mixture is randomly or sequentially partitioned into spatially separated single cells and placed into a multi-well plate, microarray, microfluidic device or slide.

[0544] Embodiment A76. A method according to embodiment A75, wherein the microarray comprises microwells, each microwell being just large enough to accommodate a single cell.

[0545] Embodiment A77. A method according to any one of embodiments A72 to A76, wherein the cells are previously sorted using a microfluidic sorter, by flow cytometry or microscopy.

[0546] Embodiment A78. A method according to any one of Embodiments A72-A77, which allows detection and quantification of at least 5, 10, 30, 50 or even more antigens in a single test.

[0547] Embodiment A79. A method according to any one of Embodiments A72-A78, wherein at least 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; 33; 34; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44; 45; 46; 47; 48; 49; or 50 antibodies are provided, each of which is associated with a unique DNA barcode.

[0548] Embodiment A80. A method according to any one of embodiments A72-A79, wherein the released DNA barcodes are sequenced by deep high-throughput sequencing.

[0549] Embodiment A81. A method according to embodiment A80, wherein the DNA barcodes are amplified prior to sequencing.

[0550] Embodiment A82. A kit comprising the antibody of any one of embodiments A27-A58 or A71, a restriction endonuclease, and optionally a pair of primers.

[0551] Embodiment B1. A method for detecting 3D molecular surface features of AAV capsid variants in a sample, comprising the following steps:

[0552] 1) forming a DNA duplex consisting of: (a) a DNA aptamer library including a sequence required for binding to an AAV capsid variant and a sequence extending from the 5' end of the target binding sequence, and (b) a single-stranded DNA (Guard-DNA or G-DNA) complementary to a region of the DNA aptamer including the 5' extension region;

[0553] 2) mixing the sample containing the target AAV capsid variant with the DNA duplex of step 1), wherein the single-stranded G-DNA molecules are released;

[0554] 3) mixing the mixture obtained in step 2) with RNase H and a single-stranded RNA complementary to the G-DNA, wherein a fluorophore and a quencher are labeled at the 5' end and the 3' end of the single-stranded RNA, respectively; and

[0555] 4) measuring the fluorescence intensity of the mixture obtained in step 3); in addition, performing droplet and / or single-cell sequencing technology.

[0556] Embodiment B2. The method according to embodiment B1, wherein the length of the single-stranded RNA is not longer than the length of the single-stranded DNA.

[0557] Embodiment B3. The method according to embodiment B1, wherein the fluorophore is selected from the group consisting of fluorescein, tetramethylrhodamine, Cy5, Cy3 and Texas Red.

[0558] Embodiment B4. The method according to Embodiment B1, wherein the quencher is selected from the group consisting of dabsyl, dabcyl and black quenchers.

[0559] Embodiment B5. The method according to embodiment B1, wherein the quencher is a fluorophore that acts as a fluorescence acceptor in a fluorescence resonance energy transfer (FRET) mechanism.

[0560] Embodiment B6. The method according to embodiment B1, wherein the AAV capsid variant particle is an antibody, a ligand, a natural compound, a synthetic peptide, or a candidate compound for a new drug.

[0561] Embodiment B7. A method according to Embodiment B1, wherein the fluorescence intensity is measured by a fluorimeter.

[0562] Embodiment B8. A DNA aptamer library for detecting 3D molecular surface features of AAV capsid variants in a sample and suitable for the method of claim 1, comprising

[0563] 1) a DNA duplex, the DNA duplex consisting of (a) a DNA aptamer library including a sequence required for binding to an AAV capsid variant and a sequence extending from the 5'-end of the target binding sequence, and (b) a single-stranded DNA (G-DNA) complementary to a DNA aptamer region including the 5'-extension region;

[0564] 2) single-stranded RNA complementary to the G-DNA, labeled with a fluorophore and a quencher; and

[0565] 3) RNase H, and wherein the length of the single-stranded RNA is not longer than the length of the single-stranded DNA.

[0566] Embodiment B9. The library according to embodiment B8, wherein the fluorophore is selected from the group consisting of fluorescein, tetramethylrhodamine, Cy5, Cy3 and Texas Red.

[0567] Embodiment B10. The library according to embodiment B8, wherein the quencher is selected from the group consisting of dabsyl, dabcyl and black quenchers.

[0568] Embodiment B11. The library according to embodiment B8, wherein the quencher is a fluorophore that acts as a fluorescence acceptor in a fluorescence resonance energy transfer (FRET) mechanism.

[0569] Embodiment B12. The library according to any one of embodiments B1-B8, wherein the AAV capsid variant particle is a protein complex comprising a capsid protein and a DNA genomic sequence.

[0570] Embodiment B13. A method for detecting 3D molecular surface features of AAV capsid variants in a sample, comprising the following steps:

[0571] 1) mixing one or more DNA aptamer libraries comprising DNA and / or RNA oligomers with one or more AAV capsid variant particles in solution, and

[0572] 2) Use droplet and / or improved single-cell sequencing technology to identify the interaction of DNA and / or RNA aptamers with one or more AAV capsid variant particles. Droplet and / or improved single-cell sequencing technology here refers to the technology and method of identifying a single AAV-DNA / RNA-aptamer complex in a droplet to be sequenced in large quantities with high sequencing accuracy, including but not limited to NGS (next generation sequencing), PacBio or nanopore sequencing technology and method.

[0573] Embodiment C1. A method of producing a DNA-encoded chemical entity, comprising:

[0574] a) reacting a first functional group of a bifunctional linker with a first chemical building block, wherein the bifunctional linker has a single functional group that reacts with the chemical building block and a single functional group that reacts with a nucleotide, nucleotide analog, nucleoside or nucleoside analog;

[0575] b) reacting the second functional group of the bifunctional linker with a single-stranded hairpin oligonucleotide comprising (i) a self-complementary region and (ii) a single-stranded loop comprising at least one natural nucleoside or nucleoside analog, thereby forming a conjugate;

[0576] c) reacting the second chemical building block with the first chemical building block of the conjugate under conditions suitable for forming a covalent bond between the first chemical building block and the second chemical building block of the conjugate; and

[0577] d) attaching a first oligonucleotide tag to the single stranded hairpin oligonucleotide of the conjugate, wherein the oligonucleotide tag comprises a region encoding the identity of the first chemical building block and / or the identity of the second chemical building block, thereby forming a DNA encoded chemical entity,

[0578] Steps (a) and (b) and / or steps (c) and (d) may be performed in any order.

[0579] Embodiment C2. A method according to embodiment C1, wherein the ligation of step (d) comprises non-enzymatic ligation.

[0580] Embodiment C3. A method according to embodiment C1, wherein the oligonucleotide label of step (d) comprises a fluorescent label or a biotin label.

[0581] Embodiment C4. A method according to embodiment C1, wherein the single-stranded hairpin oligonucleotide of step (b) comprises a region encoding the identity of the first building block.

[0582] Embodiment C5. A method according to embodiment C1, wherein the bifunctional linker is modified to increase the solubility of the DNA-encoded chemical entity under organic conditions.

[0583] Embodiment C6. A method according to embodiment C5, wherein the bifunctional linker comprises one or more of an alkyl chain, a polyethylene glycol unit, a positively charged branched species, or a hydrophobic ring structure.

[0584] Embodiment C7. A method according to embodiment C6, wherein the bifunctional linker comprises 12 to 45 polyethylene glycol units.

[0585] Embodiment C8. A method according to embodiment C1, wherein the single-stranded hairpin oligonucleotide of step (b) and / or the oligonucleotide tag of step (d) is modified to increase the solubility of the DNA-encoded chemical entity under organic conditions.

[0586] Embodiment C9. A method according to embodiment C1, wherein the oligonucleotide tag of step (d) includes a region encoding the identity of the first chemical building block.

[0587] Embodiment C10. The method of embodiment C1, wherein the oligonucleotide tag of step (d) includes a region encoding the identity of the second chemical building block.

[0588] Embodiment C11. The method according to Embodiment C1, wherein the suitable conditions of step (c) include an organic solvent.

[0589] Embodiment C12. A method according to embodiment C1, wherein the single-stranded loop of the hairpin oligonucleotide comprises a sequence that can serve as a primer binding region for amplification.

[0590] Embodiment C13. A method according to embodiment C1, wherein the bifunctional linker is attached to the 5' end of the single-stranded hairpin oligonucleotide of step (b); the bifunctional linker is embedded in the single-stranded hairpin oligonucleotide of step (b); or the bifunctional linker is located in the middle of the single-stranded hairpin oligonucleotide of step (b).

[0591] Embodiment C14. A method according to embodiment C13, wherein the bifunctional linker is attached to the 5' end of the single stranded hairpin oligonucleotide of step (b).

[0592] Embodiment C15. A method according to embodiment C13, wherein the bifunctional linker is embedded within the single-stranded hairpin oligonucleotide of step (b).

[0593] Embodiment C16. A method according to embodiment C13, wherein the bifunctional linker is placed in the middle of the single-stranded hairpin oligonucleotide of step (b).

[0594] Embodiment C17. A method according to embodiment C1, wherein the single-stranded hairpin oligonucleotide of step (b) comprises a T or C nucleotide, which comprises a fatty chain at the C5 position.

[0595] Embodiment C18. The method of embodiment C1, wherein the single-stranded hairpin oligonucleotide of step (b) comprises azobenzene.

[0596] Embodiment C19. A method according to embodiment C1, wherein the oligonucleotide tag of step (d) comprises a T or C nucleotide comprising a fatty chain at the C5 position.

[0597] Embodiment C20. A method according to embodiment C9, wherein the method further comprises attaching a second oligonucleotide tag encoding the identity of the second chemical building block to the first oligonucleotide tag.

[0598] Embodiment C21. The method according to embodiment C20, wherein the method further comprises:

[0599] (e) reacting the third chemical structural unit with the first chemical structural unit or the second chemical structural unit.

[0600] Embodiment C22. The method according to Embodiment C21, wherein the method further comprises:

[0601] (f) attaching a third oligonucleotide tag to the second oligonucleotide tag, wherein the third oligonucleotide tag encodes the identity of the third chemical building block,

[0602] Steps (e) and (f) may be performed in any order.

[0603] Embodiment C23. A method according to Embodiment C1, wherein the method further comprises:

[0604] (e) reacting one or more additional chemical building blocks with the chemical building blocks of the conjugate.

[0605] Embodiment C24. The method of embodiment C23, wherein the method further comprises:

[0606] (f) attaching one or more oligonucleotide tags to the oligonucleotide tag of the conjugate, wherein each oligonucleotide tag encodes the identity of one of the one or more additional building blocks,

[0607] Steps (e) and (f) may be performed in any order.

[0608] Embodiment C25. A method according to Embodiment C1, wherein the DNA-encoded chemical entity has an octanol:water coefficient of 1.0 to 2.5.

[0609] Embodiment C26. A method according to embodiment C1, wherein the method produces multiple DNA-encoded chemical entities.

[0610] Embodiment C27. A method according to embodiment C26, wherein the plurality comprises at least 1,000,000 different DNA-encoded chemical entities.

[0611] Embodiment C28. A method according to any one of embodiments C1 to C27, wherein the DNA-encoded chemical entity and / or library is used to mix with any AAV capsid variant in solution and / or on a solid support.

[0612] Embodiment C29. A method according to embodiment C28, wherein the mixture of DNA-encoded chemical entities and / or libraries with any AAV capsid variants in solution and / or on a solid support is sequenced by droplet and / or single cell-like sequencing technology.

Claims

1. A method for characterizing the 3D molecular surface features of AAV capsids, include: a) contacting the AAV capsid with a library of aptamers targeting one or more AAV capsids; b) removing unbound aptamers; c) eluting the bound aptamer; d) identifying the aptamer that binds to the AAV capsid; e) determining the presence and / or level of the identified aptamer; and f) characterizing the 3D molecular surface features of the AAV capsid based on the presence and / or level of the identified aptamer.

2. The method of claim 1, wherein steps a)-c) are repeated 1, 2, 3 or more times. The method according to claim 1 or 2, wherein the eluted aptamer is amplified by a PCR reaction. 4 . The method according to any one of claims 1 to 3 , wherein the aptamers in the aptamer library are linear aptamers or circular aptamers.

5. The method according to any one of claims 1 to 4, wherein each aptamer in the aptamer library comprises at least one primer binding region and a random sequence. The method according to claim 5 , wherein the primer binding region of the aptamers in the aptamer library is about 20 bp in length.

7. The method according to claim 5 or 6, wherein the random sequence of the aptamers in the aptamer library is about 36 to about 40 bp.

8. The method according to any one of claims 1 to 7, wherein each aptamer in the aptamer library comprises a double-stranded oligonucleotide sequence.

9. The method according to any one of claims 1-7, wherein each aptamer in the aptamer library comprises a single-stranded oligonucleotide sequence.

10. The method according to any one of claims 1-9, wherein at least one aptamer in the aptamer library is capable of binding to a target on the AAV capsid through the random sequence.

11. The method according to any one of claims 1 to 10, wherein each aptamer in the aptamer library comprises a single-stranded DNA (Guard-DNA or G-DNA) complementary to a region of the DNA aptamer, the region comprising the 5'-extension region.

12. The method of claim 11, wherein the single-stranded G-DNA molecule is released when the AAV capsid is contacted with the aptamer library.

13. The method of claim 10 or 11, wherein said identification of said aptamer that binds to said AAV capsid include: contacting the mixture obtained in step a) with RNase H and a single-stranded RNA complementary to the G-DNA, wherein a fluorophore and a quencher are labeled at the 5' end and the 3' end of the single-stranded RNA, respectively; and The fluorescence intensity of the mixture is measured.

14. The method of claim 13, wherein the fluorophore is selected from the group consisting of fluorescein, tetramethylrhodamine, Cy5, Cy3, and Texas Red.

15. The method according to claim 13 or 14, wherein the quencher is selected from the group consisting of dabsyl, dabcyl and black quenchers.

16. The method of any one of claims 1-10, wherein the identification of the aptamer bound to the AAV capsid is performed by sequencing.

17. The method of claim 16, wherein the sequencing comprises performing high-throughput sequencing or droplet sequencing.

18. The method according to any one of claims 1 to 17, wherein the targets of the aptamers in the aptamer library are known.

19. The method of any one of claims 1-17, wherein the precise targets of the aptamers in the aptamer library do not have to be known.

20. The method of any one of claims 1-19, wherein the AAV capsid is in solution prior to contacting with the aptamer library.

21. The method of claim 20, wherein the AAV capsid is immobilized on a support prior to contacting with the aptamer library.

22. The method of any one of claims 1-21, wherein the method further comprises characterizing additional 3D molecular surface features of the AAV capsid.

23. A method for characterizing the 3D molecular surface features of AAV capsids, include: a) contacting the AAV capsid with a DNA-encoded chemical library (DECL) comprising a pool of DNA-encoded chemical binders targeting one or more AAV capsids; b) removing unbound DNA-encoded chemical binding agents; c) eluting the bound DNA-encoded chemical binder; d) identifying a chemical binding agent encoded by said DNA that binds to said AAV capsid; e) determining the presence and / or level of the identified DNA-encoded chemical binding agent; and f) characterizing the 3D molecular surface features of the AAV capsid based on the presence and / or level of the identified DNA-encoded chemical binding agent.

24. The method of claim 23, wherein steps a)-c) are repeated 1, 2, 3 or more times.

25. The method of claim 23 or 24, wherein each DNA-encoded chemical binding agent in the DECL include: a) a compound capable of binding to one or more targets on the AAV capsid; b) DNA barcoding; as well as c) Connector.

26. The method of any one of claims 23-25, wherein the DNA barcode of the eluted DNA-encoded chemical binder is amplified by a PCR reaction.

27. The method of any one of claims 23-26, wherein the DNA barcode sequence of the DNA-encoded chemical binder is about 5 bp to about 15 bp in length.

28. The method of any one of claims 23-27, wherein the DNA barcode sequence of each DNA-encoded chemical binding agent is associated with the identity of the chemical binding agent.

29. The method of any one of claims 23-28, wherein said identification of said DNA-encoded chemical binder is performed by sequencing said DNA barcode sequence.

30. The method of claim 29, wherein the sequencing comprises performing high-throughput sequencing, droplet sequencing, or single-cell sequencing.

31. The method according to any one of claims 23 to 30, wherein the target of the DNA-encoded chemical binder in the DECL is known.

32. The method of any one of claims 23-30, wherein the precise targets of the DNA-encoded chemical binders in the aptamer library do not have to be known.

33. The method of any one of claims 23-32, wherein the AAV capsid is in solution prior to contacting with the DECL.

34. The method of claim 33, wherein the AAV capsid is immobilized on a support prior to contacting with the DECL.

35. The method of any one of claims 25-34, wherein the linker is a cleavable linker.

36. The method of any one of claims 23-35, wherein the method further comprises characterizing additional 3D molecular surface features of the AAV capsid.

37. A method for characterizing the 3D molecular surface features of AAV capsids, include: a) contacting the AAV capsid with a DNA-encoded antibody library (DEAL) comprising a pool of DNA-encoded antibody binders that target one or more AAV capsids; b) removing unbound DNA-encoded antibody binder; c) eluting the bound DNA-encoded antibody binder; d) identifying an antibody binder encoded by said DNA that binds to said AAV capsid; e) determining the presence and / or level of the identified DNA-encoded antibody binder; and f) characterizing the 3D molecular surface features of the AAV capsid based on the presence and / or levels of the DNA-encoded antibody binders identified.

38. The method of claim 37, wherein steps a)-c) are repeated 1, 2, 3 or more times.

39. The method of claim 37 or 38, wherein each DNA in the DECL encodes an antibody binding agent include: a) an antibody or antigen-binding fragment thereof capable of binding to one or more targets on the AAV capsid; b) DNA barcoding; as well as c) Connector.

40. The method of any one of claims 37-39, wherein the DNA barcode of the eluted DNA-encoded antibody binder is amplified by a PCR reaction.

41. The method of any one of claims 37-40, wherein the DNA barcode sequence of the DNA-encoded antibody binder is about 5 bp to about 15 bp in length.

42. The method of any one of claims 37-41, wherein said identification of said DNA-encoded antibody binder is performed by sequencing.

43. The method of claim 42, wherein the sequencing comprises performing high throughput sequencing or droplet sequencing.

44. A method according to any one of claims 37-43, wherein the target of the antibody binder encoded by the DNA in the DEAL is known.

45. The method of any one of claims 37-44, wherein the precise target of the DNA-encoded antibody binder in the DEAL library does not have to be known.

46. ​​The method of any one of claims 37-45, wherein the AAV capsid is in solution prior to contacting with the DEAL.

47. The method of claim 46, wherein the AAV capsid is immobilized on a support prior to contacting with the DEAL.

48. The method of any one of claims 39-47, wherein the linker is a cleavable linker.

49. The method of claim 48, wherein the linker comprises at least one nucleic acid molecule comprising an enzymatically cleavable sequence (CL).

50. The method of any one of claims 37-49, wherein the method further comprises characterizing the 3D molecular surface features of additional AAV capsid(s).

51. A method for enriching a binding library for characterizing the 3D molecular surface features of AAV capsids, include: (a) contacting a pool of binding reagents with a first population of AAV capsids; (b) enriching a sub-pool of binders that bind to said first population of AAV capsids, thereby enriching said binding library for characterizing the 3D molecular surface features of said AAV capsids.

52. The method according to claim 51, further comprising: include: (c) contacting said subpool of binding agents that bind to said first population of AAV capsids with a second population of AAV capsids; as well as (d) depleting a second sub-pool of binders that display affinity for said second population of AAV capsids, thereby selecting a population of binders that have preferential affinity for said first population of AAV capsids.

53. The method of claim 51 or 52, wherein the library of binding agents is an aptamer library, including a DNA-encoded chemical library (DECL) or a DNA-encoded antibody library (DEAL).

54. The method of any one of claims 1-53, wherein the AAV capsid or the first population of AAV capsids comprises one or more of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVhu.37, AAVrh.8, AAVrh.10, AAVrh.39, AAV11, AAV12, and AAV13 and other variants derived from mutations, peptide insertions, or shuffling.

55. The method of any one of claims 1-54, wherein the 3D molecular surface feature is a binding property of the library.

56. The method of claim 55, wherein the binding characteristic is the number, sequence and copy number of the binding reagents bound.

57. The method of any one of claims 1-56, wherein the 3D molecular surface features of the AAV capsid are indicative of the tropism and / or neutralization properties (e.g., the ability to evade neutralizing antibodies).

58. A kit for performing a method of enriching a binding library according to any one of claims 51-57.

Citation Information

Patent Citations

  • DNA-encoded chemical libraries

    WO2009077173A2